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Hereditary hearing impairment
In recent history, remarkable progress has been made in our understanding of the
basic principles of hereditary hearing impairment. The insight that heredity was a
major cause of hearing impairment first appeared in the second edition of Adam
Politzer’s Lehrbuch der Ohrenheilkunde, in 1887.1 Adam Politzer (1853-1920), an
Austrian otologist, based his conclusions on the works of Wilde and Hartmann. Sir
William Wilde (1815-1876), also an otologist, was medical commissioner during the
Irish census in 1841 and the first to describe “direct” or dominant inheritance in
hearing impairment.22 The German otologist Arthur Hartmann (1849-1931) was the
first to describe the pattern of “indirect” or recessive inheritance in hearing
impairment based on the, at that time relatively unappreciated, work of Gregor
Mendel (1822-1884).3,4
In the nineteenth century, most research on hereditary hearing impairment
concentrated on syndromes, such as Usher syndrome, with hearing impairment as
one of the main features.5 With the introduction of the audiometer in the late 1930s,
the non-syndromic types of hearing impairment slowly came into focus. The
audiometer, which enabled physicians to assess the degree of hearing impairment,
gradually became more widely available after the Second World War. In 1953
Watson and Crick opened up a new world with their discovery of the structure of
DNA.6 However, it was not until 1992 that Léon et al. were the first to map the
chromosomal locus for a gene responsible for nonsyndromic autosomal dominant
hearing impairment.7
In  neonates,  genetic  defects  are  responsible  for  at  least  50%  of  the  cases  with
hearing impairment. About 30% of those with hereditary hearing impairment have
other associated anomalies, and about 70% have no other features - these are
classified as syndromic and nonsyndromic, respectively. In nonsyndromic hereditary
hearing impairment, the pattern of inheritance can be autosomal recessive (70-
80%), autosomal dominant (20-30%), X-linked (<1%), or mitochondrial (<1%). In
general, nonsyndromic autosomal recessive hearing impairment is usually
progressive and often more severe than nonsyndromic autosomal dominant hearing
impairment.
Since the early 1990s, over 100 types of nonsyndromic sensorineural hearing
impairment (SNHI) have been identified.8 The gene loci for nonsyndromic types of
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hearing impairment have been designated DFN (DeaFNess) and are numbered in
chronological order of discovery (e.g. DFNA1). Autosomal dominant types are
referred to as DFNA, autosomal recessive types as DFNB, and X-linked types as DFN.
Autosomal dominant types of hearing impairment especially can be characterised
by audiometric configuration, age of onset (congenital, early, late onset), degree of
progression, and severity of hearing impairment (according to the GENDEAF criteria:
mild, 20-40 dB; moderate, 41-70 dB; severe, 71-95 dB; profound, >95dB).9
This PhD thesis focuses on DFNA8/12, Usher syndrome type III, and Wolfram
syndrome; one type of nonsyndromic, autosomal dominant hearing impairment and
two types of syndromic, autosomal recessive hearing impairment. This introduction
will first concentrate on midfrequency hearing impairment, DFNA8/12, and
subsequently, on Usher syndrome type III, and Wolfram syndrome.
Midfrequency hearing impairment
Konigsmark and Gorlin (1976) were among the first to distinguish types of non-
syndromic sensorineural hearing impairment by the shape of the audiogram.10 An
example of a typical audiometric configuration is midfrequency hearing
impairment, also described as “cookie-bite”, U-shaped, or trough-shaped
configuration (Figure 1). This type of hearing impairment can be seen in families
with DFNA8/12, DFNA13, DFNA21, DFNA31, DFNA44, and DFNA4911-20
Figure 1. Audiogram of individual with DFNA8/1221.
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Hearing loss primarily involving the mid-frequencies was first described in single
families by Mårtensson (1960), and Williams and Roblee (1962), and later in
additional families by Paparella et al. (1969) and Konigsmark et al. (1970).22-25
Paparella et al. also described temporal bone histopathology in a father and
daughter with midfrequency hearing impairment.24 They observed a loss of ganglion
cells, atrophy of the stria vascularis and degeneration of the organ of Corti.24
Sensorineural midfrequency hearing impairment is very rare.26
DFNA8/12 (TECTA)
The first two reports on the genetics of non-syndromic, autosomal dominant mid-
frequency hearing impairment describe an Austrian family (DFNA8) and a Belgian
family (DFNA12).11-13 The proposed linkage to chromosome 15q in the Austrian family
was later withdrawn and revised to chromosome 11q22-24.11,12 When the causative
mutations for both families were shown to be located in the same gene (TECTA), the
locus was designated as DFNA8/12.27 Subsequently, other mutations were found in
families originating from Sweden, France, Spain, Japan and Turkey.28-32 Table 1 lists
the reported families with their mutations, affected domains and phenotypes.
Table 1. DFNA8/12 TECTA mutations and their associated phenotype
Origin Mutation Domain Onset Phenotype Freq.
French29 C1619S ZA Variable Mild to moderate-severe, progressive High
Swedish28 C1057S ZA Postlingual Mild to severe, progressive High
Turkish32 C1509G ZA Prelingual Mild to moderate, progressive High
Spanish30 C1837G ZP Postlingual Mild to moderate, progressive Mid
Austrian11 Y1870C ZP Prelingual Moderate, stable Mid
Belgian12 L1820F, G1824D ZP Prelingual Moderate, stable Mid
Japanese31 R2021H ZP Prelingual Mild to moderate, stable Mid
The TECTA gene encodes the protein ?-tectorin, an important noncollagenous
component of the tectorial membrane in the cochlea. Alpha-Tectorin is expressed at
high levels during tectorial membrane morphogenesis, between the 12th and 20th
week of embryonic development, after which it decreases dramatically.12,32,33 The
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tectorial membrane consists of an extracellular matrix overlying the organ of Corti,
and contacts the outer hair cells (Figure 2).
Figure 2. The organ of Corti.34
The ?-tectorin protein is composed of three distinct modules: the entactin G1
domain, the zonadhesin (ZA) domain with von Willebrand factor type D repeats and
the zona pellucida (ZP) domain.35 These domains are cross-linked to each other and
?-tectorin by disulfide bridges to form the non-collagenous matrix of the tectorial
membrane.35,36
Mutations affecting the ZP domain are associated with midfrequency hearing
impairment, whereas mutations in the ZA domain are associated with hearing
impairment primarily affecting the high frequencies (table 1).11,12,28-32 Additionally,
mutations causing substitution of cysteine residues are associated with progressive
hearing impairment (table 1).11,12,28-32
In 1999 Mustapha et al. analysed a large consanguineous family with autosomal
recessive nonsyndromic, severe to profound hearing impairment and identified a
new  locus,  designated  DFNB21  on  chromosome  11q23,  the  same  region  as TECTA.27
Sequence analysis of TECTA revealed a homozygous disease-causing mutation, thus
demonstrating that mutations in TECTA can cause either dominant or recessive
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types of hearing impairment.27 The fact that heterozygous carriers of this mutation
had normal hearing suggests that the mutations in DFNA8/12 exert a dominant-
negative effect, while mutations in DFNB21 have a loss of function effect.27
TECTA mouse models
Legan et al. studied mice deficient in ?-tectorin by a targeted disruption (?ENT) in
Tecta that removes the entactin G1-like domain of ?-tectorin, as well as mice with an
Y1870C mutation in the zona pellucida domain of Tecta.37,38 Mice homozygous for a
targeted disruption (Tecta?ENT/?ENT) are functional nulls for ?-tectorin and have
tectorial membranes that are detached from the cochlear sensory epithelium and
lack all non-collagenous matrix, leading to hearing impairment, whereas
heterozygous mice (Tecta?ENT/+) have normal tectorial membranes and normal
hearing.37 Homozygosity for recessive, predicted null alleles of ?-tectorin in humans
might exert a similar effect upon the tectorial membrane.39
In  mice  heterozygous  for  a  Y1870C  mutation  (TectaY1870C/+) the matrix structure of
the tectorial membrane is disrupted (Figure 3).38 Figures 3a-c show the light-
microscopic analysis of the cochlea and organ of Corti in Tecta+/+, TectaY1870C/+, and
TectaY1870C/Y1870C mice. In the TectaY1870C/+ mouse there is a considerable reduction in
thickness of the limbal attachment zone (LZ) of the tectorial membrane, an absence
of a marginal band (MB: a dense thickening running around the peripheral margin)
and Hensen’s stripe (HS: a ridge that runs longitudinally along the underside of the
tectorial membrane adjacent and parallel to the bundles of the inner hair cells), and
detachment of Kimura’s membrane (arrowhead in Fig. 3b).38 In  the TectaY1870C/Y1870C
mouse, the tectorial membrane (arrow in Fig. 3c) is completely detached from the
spiral limbus and the surface of the organ of Corti.38
The changes observed in the TectaY1870C/+ mouse do not seriously influence the
tectorial membrane’s role in ensuring optimal cochlear feedback, however, neural
thresholds were elevated and neural tuning curves were broadened.38 Therefore, the
TectaY1870C/+ mouse may be a model for DFNA8/12(TECTA).
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Figure 3a-c. Organ of Corti and tectorial membrane in mouse models.38 Light microscopic
toluidine blue-stained, 1-?m-thick sections of the cochlear duct. Fig 3a: limbal attachment
zone (LZ) of the tectorial membrane, marginal band (MB), and Hensen’s stripe (HS). Fig 3b:
detachment of Kimura’s membrane (arrowhead). Fig 3c: detached tectorial membrane
(arrow). Bars: 50 ?m.
Chapter 2.1 presents a review on DFNA8/12 (in Dutch). Chapter 2.2 describes a new
mutation in a Dutch DFNA8/12(TECTA) family, confirming the genotype-phenotype
correlation. In chapter 2.3, an extensive and unique audiological evaluation of
selected members from this family is presented to elucidate specific audiological
features.
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Usher syndrome
Usher syndrome, an eponym of the Scottish ophthalmologist Charles Howard Usher
(1865-1942), is an autosomal recessive disorder that is characterised by the
combination of SNHI and retinitis pigmentosa (RP). Usher syndrome was first
described in 1858 by Albrecht von Graefe, a famous ophthalmologist, who reported
on  a  patient  and  two  of  his  sibs.5 Soon  after,  his  student  Richard  Liebreich  (1861),
another German ophthalmologist, examined the deaf children of Berlin and
observed a higher prevalence of the combination of RP and hearing impairment in
the Jewish community.40 In those days, the autosomal recessive pattern of
inheritance was not yet fully understood. Finally, in 1935 the disease was named
after Charles Howard Usher, who dedicated his life to study visually impaired
patients and their families and emphasized the hereditary nature of the disorder in
his book entitled “on the inheritance of retinitis pigmentosa”.41
In 1977, Davenport and Omenn introduced a clinical classification of Usher syndrome
and  after  several  modifications  it  now  comprises  three  different  types  (I-III)  as  is
shown in table 2.42 Usher syndrome type I is characterised by congenital, profound
SNHI, RP and vestibular areflexia. Usher syndrome type II shows moderate-to-severe
congenital highfrequency SNHI, RP and intact vestibular responses. Usher syndrome
type III generally shows progressive SNHI, RP and variable vestibular responses. RP
leads to impaired dark adaptation and night blindness, progressive visual field
constriction and reduction in visual acuity in all types of Usher syndrome and may
result in blindness.
Table 2. Modified clinical classification of Davenport and Omenn.42
Type Hearing impairment Onset of RP Vestibular responses
I Congenital profound Onset in first decade Absent
II Congenital sloping audiogram Onset in first or second decade Intact
III Progressive Variable Variable
In 2001 Otterstedde et al. proposed a new classification for Usher syndrome type I
after the observation of intact vestibular function in profoundly hearing impaired
patients.43 These clinically diagnosed Usher syndrome type I patients, however, were
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never genetically classified and may in fact be Usher syndrome type III patients with
early onset of highly progressive sensorineural hearing impairment.43
Davenport et al. found that about 90% of reported cases had profound congenital
deafness with onset of RP before puberty, whereas the rest had moderate to severe
hearing impairment from birth and RP beginning after puberty.44 In  1989
Karjalainen et al. reported a remarkably high prevalence of progressive hearing
impairment in Usher syndrome patients in Finland.45
Usher syndrome was estimated to occur in 3.0 per 100,000 in Scandinavia and 4.4
per 100,000 in the United States.46,47 The overall prevalence ranges from 3.5 to 6.2
per 100,000, making Usher syndrome the most common cause of deaf-blindness
worldwide.47-51 European  studies  show  a  proportion  of  25-44%  of  Usher  syndrome
type I  and 56-75% of Usher syndrome type II48-51 A recent study by Kimberling et al.
estimated  that  for  the  most  common  genetic  subtypes  USH1B  and  USH2A  the
population rate is approximately 1 in 70,000 and 1 in 17,000, respectively. The carrier
frequency was estimated to be 1 in 132 for USH1B and 1 in 65 for USH2A.52
Since Kimberling et al. in 1990 mapped the first locus (USH2A) to chromosome 1q41,
Usher syndrome has proved to be genetically heterogenous.8,53 Until  now,  6
chromosomal loci have been identified for Usher type I (USH1B-G), two loci for Usher
type II (USH2A, C) and only one locus for Usher type III (USH3A).8 At present, 8 genes
(MYO7A, USH1C, CDH23, PCDH15, SANS, USH2A, VLGR1, and USH3A) have been
identified (Table 3).8 Recently, the presumed USH1A locus on 14q32, as described by
Kaplan et al.,54 was retracted because 7 out of the 9 reported families harboured
mutations in the myosin VIIA gene, 1 was compatible with linkage to the USH1D and
USH1E loci, and 1 excluded all USH1 loci (including the 14q32 region).55 Furthermore,
the original USH2B family, mapped to chromosome 3p23-24 by Hmani et al., proved
to be linked to  USH2C.56,57 Table 3 provides an overview of the genetic subtypes of
Usher syndrome.
The proteins encoded by the eight established Usher syndrome genes belong to
different protein families. The USH1B protein is the molecular motor myosin VIIa.58
The USH1D and USH1F genes encode cell-to-cell adhesion proteins, cadherin 23 and
protocadherin 15.62-64
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Table 3. Genetic subtypes of Usher syndrome.8
Type Genetic subtype Location Gene References
I USH1B 11q13.5 MYO7A 58
USH1C 11p15.1 USH1C 59-61
USH1D 10q22.1 CDH23 62-64
USH1E 21q21 Unknown 65
USH1F 10q21-22 PCDH15 66,67
USH1G 17q24-25 SANS 68,69
II USH2A 1q41 USH2A 53,70,71
USH2C 5q14.3-q21.3 VLGR1 72,73
III USH3A 3q21-q25 USH3A 74,75
The USH1C and USH1G genes encode scaffold proteins harmonin and SANS.76,77
Usherin is a transmembrane protein that is involved in USH2A and the G-protein-
coupled 7-transmembrane receptor (VLGR1) in USH2C.53,70-73 The USH3A gene codes
for clarin-1, a member of the clarin family that has 4 transmembrane domains.78
Recent studies have shown that, although there are big differences in phenotype,
the USH1 and USH2 proteins are integrated in an Usher protein interactome.79-82 The
USH3A protein clarin-1 has, so far, not been proven to be part of the Usher protein
interactome.80
Mutations in the different Usher genes can lead to a broad spectrum of phenotypes
in the ear and eye, but there is increasing evidence for the existence of an integrated
Usher protein network in both the inner ear and the retina.79,81,82 The Usher protein
complex in inner ear and retina seems to have its major function in the
neurosensory cells, respectively in the hair cells and photoreceptor cells.83 In the
inner ear, hair bundles are located at the apical surface of both auditory and
vestibular hair cells.83
The major sites of colocalization of Usher proteins in the inner ear are the stereocilia
and the synaptic regions of hair cells.79,81,82,84,85 In addition, the spiral ganglion
neurons harbour several of the Usher proteins such as usherin, protocadherin 15, and
clarin-1.67,78,82 In the cuticular plate, harmonin and myosin VIIa are co-expressed.76,86-
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88 Cadherin 23 is also found in Reissner’s membrane and SANS, protocadherin 15 and
usherin in the supporting cells.67,81,89
In the retina, the Usher proteins co-localize in the outer plexiform layer of the
photoreceptor, as well as in the ciliary region between the outer- and inner
segments, and the calycal processes.77,79,80,82,86,90-93
Genotype-phenotype correlation
In recent years, a lot of research has been performed on genotype-phenotype
correlation in Usher syndrome patients, in order to provide clinicians with essential
information to obtain a correct clinical diagnosis and to inform the patients and
their relatives about the prognosis of their disease.
Usher  syndrome  type  I  patients  have  a  congenital  severe  to  profound  SNHI,
congenitally absent or severely diminished vestibular responses, and RP with
subsequent impairment of vision, starting in the first decade of life. Later in
childhood, patients develop decreased peripheral vision that progresses into tunnel
vision over decades.94 Visual acuity also deteriorates with increasing age.94 Due to
their vestibular areflexia, children with Usher syndrome type I have delayed
developmental milestones and do not start walking until the age of 18-24 months.
USH1B is the most common subtype with an estimated prevalence of 45-60% in
Usher syndrome type I.52
Usher syndrome type II (USH2A) patients have congenital moderate to severe SNHI
with a downsloping audiogram, normal vestibular responses and RP with onset in
the first or second decade. However, intra and interfamilial variation in this
phenotype can be observed. SNHI can be progressive by about 0.5 dB per year for all
frequencies.95 Visual impairment increases similarly to USH1B with advancing age.94
Children with Usher syndrome type II usually have normal milestones. USH2A is the
most common subtype (80%) of Usher syndrome type II. Figure 4 shows age-related
typical audiograms (ARTA) for USH1B and USH2A.
In a retrospective study on visual impairment in patients with Usher syndrome types
I and II, Sadeghi et al. found that progressive loss of visual acuity and visual field size
attains a substantial degree between the second and third decade of life. They
concluded that the rate of degeneration varies between individuals in both types of
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Usher syndrome. However, in this study around 70% retained good reading vision
until the age of 60 years or more.98
Figure 4. ARTA of USH1B and USH2A (age in years in italics).96,97
The genetic subtypes USH1B and USH2A account for 75-80% of all Usher patients
worldwide, whereas USH3A is rare (~2%).99,100 However,  Usher  syndrome type III  is
common in Scandinavian countries, especially in Finland.
Usher syndrome type III
As mentioned before, Karjalainen et al. reported a remarkably high prevalence of
progressive hearing impairment in Usher syndrome patients in Finland.45 A
nationwide study conducted by Pakarinen et al. confirmed that Usher syndrome
type III accounts for 40% of all Finnish Usher patients and therefore is the most
common form of Usher syndrome in Finland.101 Formerly, Usher syndrome type III in
Finland was called dystrophia retinae pigmentosa – dysacusis (DRD) syndrome or
Nuutila disease.102 The high prevalence of this syndrome can be explained by taking
notion of the Finnish Disease Heritage, a collection of nearly 40 rare hereditary
diseases over-represented in Finland.102,103 The Finnish Disease Heritage is the result
of the Finnish demographic history, which is characterised by the presence of
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national and regional isolates with rapid expansion.103 Specific mutations that
probably have been imported by early immigrants have been enriched all over the
country.104 The associated Finnish founder mutation identified in nearly all Usher
syndrome type III cases is the Finmajor mutation in the USH3A gene on chromosome
3q21-q25 that changes codon for a tyrosine into a premature stop codon and leads to
a truncated protein.75,78
The USH3A gene encodes the protein clarin-1, which is expressed in several tissues
including the sensory epithelia of the auditory and visual system.75,78 In the inner ear,
clarin-1 expression is found in the inner and outer hair cells of the organ of Corti and
spiral ganglion cells that contain the primary neurons that innervate the cochlear
sensory epithelia.78 Adato et al. suggested that clarin-1 has a role in the excitatory
ribbon synapse junctions between hair cells and cochlear ganglion cells, as well as in
analogous synapses within the retina.78,105
Pakarinen et al. studied 42 Usher syndrome type III patients and stated that hearing
impairment in this type of Usher syndrome most often has a postlingual onset and
progresses in 5-30 years to severe or profound levels.101 They also performed
ophthalmologic examinations and reported these patients to have predominant
hypermetropia with astigmatism, as opposed to hypermetropia without
astigmatism in Usher syndrome type I patients and myopic refractive errors in Usher
syndrome type II patients.106 Recently, Sadeghi et al. studied 28 patients with Usher
syndrome type III and concluded that 35% of the patients had severe hearing
impairment at an early age (4 to 6 years); progression began in the first decade and
approximately 50% of the patients became profoundly deaf by the age of 40.107
Vestibular function was variable, ranging from normal to vestibular dysfunction.107
Patients with Usher syndrome type III can be misdiagnosed as having Usher
syndrome type I or Usher syndrome type II.107,108
Chapters 3.1 and 3.2 of this thesis provide a detailed audiometric and ophthalmologic
evaluation of Finnish Usher syndrome type III patients, resulting from close co-
operation with our Finnish colleagues. Auditory and visual features were compared
with data previously reported for Dutch USH1B and USH2A patients. The results of
this study contribute to the understanding of the genotype-phenotype correlations
in all types of Usher syndrome.
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Wolfram syndrome
Wolfram syndrome is an autosomal recessive inherited deaf blindness syndrome
that is characterized by Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and
Deafness (DIDMOAD). Wolfram syndrome is rare, with an estimated prevalence of
1:770,000.109 The first report on the association of diabetes mellitus and optic
atrophy in siblings was made by Wolfram and Wagner in 1938.110 In 1949 De Lawter
added the feature diabetes insipidus.111 Tunbridge, in his 1956 study on the
syndromic association, reported on Wagner’s unpublished observation that 3 out of
4 patients had subnormal hearing.110,112 In 1977, Cremers et al. named the association
Wolfram syndrome in their systematic literature review of 88 cases.113
Insulin-dependent diabetes mellitus and bilateral optic atrophy are the minimal
features necessary to establish the diagnosis of Wolfram syndrome. Typically,
diabetes mellitus is detected first at a mean age of 6 years, followed by optic
atrophy at a mean age of 11 years. Hypothalamic diabetes insipidus, which occurs in
73% of the patients, and SNHI (62%) usually present in the second decade of life.109
In addition to these four classical features, patients can develop renal tract
complications (58%) in the third decade, neurological complications such as
cerebellar ataxia or myoclonus (62%) in the fourth decade, behavioural and
psychiatric illness (60%), gastro-intestinal dysmotility (24%) and primary gonad
atrophy.109,114 Swift et al. reported that relatives of Wolfram syndrome patients who
are a heterozygous carrier of a WFS1 mutation, are 26-fold more likely to require
psychiatric hospitalization than non-carriers.115 Later, the same authors estimated
the relative risk for admission for psychiatric illness to be 7.1.116 Other reported
features are upper gastrointestinal ulceration and bleeding, heart malformations
and anterior pituitary dysfunction.117,118 In general, Wolfram syndrome represents a
progressive neurodegenerative disorder that affects central, peripheral and
neuroendocrine components of the nervous system resulting in death around the
age of 40.119
In 1998, two research groups reported the WFS1 gene, located on chromosome
4p16.1, to be involved in Wolfram syndrome.120,121 WFS1 encodes  wolframin,  a
transmembrane protein that consists of 890 amino acids.121 Wolframin is expressed
in the endoplasmatic reticulum of a number of cell types in heart, lung, brain and
pancreas.121,122 Immunostaining in developing murine inner ear showed that
wolframin localizes to the canalicular reticulum, a specialized form of
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endoplasmatic reticulum.123 The canalicular reticulum has been identified in various
types of inner ear cells, including vestibular and cochlear hair cells, spiral ganglion
cells, Deiter’s cells and cells in the stria vascularis and is suggested to be involved in
intercellular ion transport, an important process in the physiology of the inner
ear.119,123
The discovery of the WFS1 gene weakened the earlier hypothesis that deletions and
pathogenic point mutations in mitochondrial DNA are responsible for Wolframe
syndrome.124,126 In 2000 Barrett et al. investigated a cohort of 50 patients, and found
no abnormal mitochondrial (mt) function or mtDNA mutations and concluded that
there is no evidence supporting a role for mtDNA in Wolfram syndrome.127 This was
confirmed in a study by Domenech et al. who identified WFS1 mutations in six
Wolfram syndrome families without evidence of mitochondrial mutations.128
Genotype-phenotype correlation
Mutations in WFS1 can also result in an autosomal dominant form of non-syndromic
SNHI classified as DFNA6/14/38.129,130 In contrast to Wolfram syndrome,
DFNA6/14/38 is characterized by low-frequency SNHI.131 Hearing impairment in
DFNA6/14/38 can be either progressive or non-progressive.131 Mutation analysis of
WFS1 in families with DFNA6/14/38 revealed that the identified pathogenic
mutations in this disorder all are small non-inactivating (missense) mutations,
whereas  most  of  the  pathogenic  mutations  in  Wolfram  syndrome  patients  are
inactivating mutations.132 The on-line WFS1 gene mutation and polymorphism
database lists all documented mutations for DFNA6/14/38 and Wolfram
syndrome.133
The majority of mutations underlying Wolfram syndrome are nonsense, frameshift,
or significant insertions or deletions expected to produce a functionally null protein.
However, a significant proportion of the mutations in Wolfram syndrome are
missense or small in-frame insertions or deletions expected to produce a functional
protein. This lead McHugh and Friedman to hypothesize that the phenotypic
spectrum of Wolfram syndrome is also influenced by modifier genes.119
El-Shanti  et  al.  found  a  second  locus  for  Wolfram  syndrome  (WFS2) in three
Jordanian families, located on chromosome 4q22-24.117 All affected family members
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were diagnosed with diabetes mellitus and optic atrophy, but remarkably, none of
theses patients had diabetes insipidus.117
Hearing impairment in Wolfram syndrome
In  2004,  Pennings  et  al.  reported  on  11  Dutch  Wolfram  syndrome  patients  with
confirmed mutations in WFS1.134 They concluded that progression in hearing
impairment mainly occurred in the mid- and high-frequency range.134 In addition,
they observed that the hearing impairment in 5 female patients with Wolfram
syndrome was substantially worse when compared to the hearing impairment in 4
male patients.134 They hypothesised that this gender-related difference in hearing
impairment might be explained by the involvement of estrogen.134 Figure 5 shows
the binaural mean audiogram of five female and four male patients.
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Figure 5. Gender-related hearing impairment in Wolfram patients. Patients are represented
with squares (male) and circles (females).134
To further outline the feature of sensorineural hearing impairment in Wolfram
syndrome in terms of presence and degree of progression and degree of variability
and to evaluate whether the degree of hearing impairment in Wolfram syndrome
patients is gender-related an international multicentre study was conducted.
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Chapter 4 of this thesis provides a comprehensive evaluation of hearing impairment
in this multicentre study of genotyped Wolfram syndrome patients.
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Van gen naar ziekte; DFNA8/12, een autosomaal
dominant overervend komvormig perceptief
gehoorverlies
Cor W.R.J. Cremers, Rutger F. Plantinga, Hannie Kremer.
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Abstract
An autosomal dominant inherited disorder known as DFNA8/12 causes mild-to-
moderate/severe midfrequency or mild-to-severe progressive highfrequency
sensorineural hearing impairment. The causative gene, TECTA, encodes ?-
tectorin, the most important noncollagenous component of the tectorial
membrane  in  the  cochlea  and  the  otolith  membrane  in  the  maculae  of  the
vestibular system. Mutations in the zona pellucida domain of ?-tectorin cause
midfrequency hearing impairment, whereas mutations in the zonadhesin domain
cause progressive highfrequency hearing impairment. The intact hearing in the
low and high frequencies may prohibit successful correction with a hearing aid.
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De ziekte
Een "komvormig" perceptief gehoorverlies dat al aanwezig is op kinderleeftijd is
uitzonderlijk. In een deel van de gevallen betreft het meerdere familieleden. In het
toonaudiogram is het gehoorverlies het grootste in de middenfrequenties 500-2000
Hz en het geringste voor de lagere en hogere tonen. Een dergelijke toonaudio-
metrische curve heeft dan een komvorm, heel instructief ook wel "cookie-bite"-
audiogram genoemd. Het is aannemelijk dat het om een aangeboren gehoorverlies
gaat. Toch blijft het gehoorverlies lang onopgemerkt, omdat er in het hogere
tonengebied een tamelijk normale gehoorgevoeligheid is en daar de spraak beter
verstaan wordt. Zoals normaal horenden bij het verstaan in een zeer rumoerige
omgeving om beter te horen uitwijken naar het gebied van de hoge tonen, zo geldt
voor deze personen met een komvormig gehoorverlies dat zij niet anders kunnen.
Komvormig gehoorverlies kan geïsoleerd en onverklaard vóórkomen. Een
autosomaal dominant overervende vorm is al bekend sinds de jaren vijftig en zestig
van de vorige eeuw.1 2 Toen is de aandoening in families beschreven en is vastgesteld
dat het gehoorverlies met de leeftijd toeneemt. In de jaren negentig van de vorige
eeuw werd het mogelijk door in veelvuldig aangedane families genkoppelings-
studies en daaropvolgend genidentificatie te verrichten om de niet-syndromale
autosomaal dominant voorkomende vormen van slechthorendheid van elkaar te
onderscheiden. De codering DFNA werd verkozen met een nummer als toevoeging
om deze nieuw herkende ziektebeelden te benoemen. DFN staat voor "deafness" en
de A staat voor "autosomaal dominant overervend". Het toegevoegde nummer geeft
de volgorde in de tijd aan waarop de aandoening via genkoppeling geïdentificeerd
werd. In dit geval bleken een Oostenrijkse en een Belgische familie met een
middenfrequentieslechthorendheid, die eerder vanwege verschillende genkoppe-
lingsresultaten afzonderlijk DFNA8 en DFNA12 benoemd waren, toch eenzelfde
gebied voor genkoppeling en eenzelfde aangedane gen TECTA als grondslag te
hebben.3 4 De benaming werd daardoor DFNA8/12.
Sommige families met DFNA8/12 laten gehoorverlies in met name de hoge tonen
zien. Het gen voor DFNA8/12 werd TECTA genoemd, omdat bij deze ziekte de
tectoriale membraan is aangedaan.
Immers, het gen TECTA codeert voor ?-tectorine, dat de belangrijkste niet-collagene
component van de tectoriale membraan in de cochlea en de otolietenmembraan in
de maculae van het vestibulaire systeem is.
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De tectoriale membraan bestaat uit een extracellulaire matrix die over het orgaan
van Corti heen ligt en in contact staat met de buitenste haarcellen (figuur 1). Deze
tectoriale membraan speelt door de aandrijving van de haarcellen een belangrijke
rol bij overdracht van geluid aan de haarcellen in de cochlea.5 Deze kennis maakt
inzichtelijk waarom er bijzondere audiometrische bevindingen verwacht kunnen
worden.6
Figuur 1. Illustratie van het binnenoor, met in detail een doorsnede van het Orgaan van
Corti.
Bijzondere audiometrische bevindingen en de behandeling
Op zichzelf is een komvormig audiogram al een bijzondere bevinding. Het
vóórkomen daarvan binnen een familie wijst naar een erfelijke bepaaldheid en dan
gaat het om een zich herhalende aandoening met eenzelfde onderliggende stoornis.
Bijzonder is dat bij DFNA8/12 de geluidsoverdracht in het binnenoor verstoord is en
wel voordat het eigenlijke zintuiglijke orgaan van Corti bereikt wordt. Het gaat
daarmee om een geleidingsslechthorendheid in het binnenoor, zoals er ook bij een
aandoening in het middenoor een geleidingsstoornis is.6 Een en ander betekent dat
met hoortoestellen het probleem van onvoldoende geluidsoverdracht volledig
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gecorrigeerd kan worden om een verder intact zintuiglijk orgaan van Corti aan te
sturen.  Voorwaarde  blijft  dat  het  gehoorverlies  in  de  hoge  en  lage  tonen  ook
voldoende groot is om een hoortoestelaanpassing succesvol te kunnen laten zijn. Bij
een dergelijk type binnenoor-gehoorverlies zal niet het bezwaar optreden dat de
versterking van het geluid snel te sterk is en als te luid wordt ervaren.
Bij een licht tot 40 dB groot komvormig gehoorverlies met een bijna normaal gehoor
in de hogere en lagere tonen kan een aanpassing van een hoortoestel mislukken
door teveel hinder van omgevingsgeluiden (lage tonen) en een nog te goed verstaan
in de hogere tonen. Een en ander betekent dat de revalidatiemogelijkheden vooral
voor schoolgaande kinderen met DFNA8/12 veelal onvoldoende zijn om hen op-
timaal te laten functioneren. Het gehoorverlies is in sommige families progressief.
Multidisciplinaire begeleiding vanuit een kinderaudiologisch centrum is aange-
wezen om elke patiënt optimaal te kunnen begeleiden.
Het gen
Het TECTA-gen is gelegen op chromosoom 11q23.3 en bestaat uit 23 exonen. Het
messenger-RNA is 6468 basenparen lang en codeert voor een eiwit, ?-tectorine, van
2155 aminozuren (Ensemble Human Genome; www.ensembl.org/homo_sapiens).
Het gen komt alleen in het binnenoor hoog tot expressie. Het eiwit bestaat uit
verschillende domeinen waaronder het zona-pellucida- en het zonadhesine-domein.
Mutaties in TECTA-gen die het zona-pellucidadomein veranderen, veroorzaken een
middenfrequentieslechthorendheid, terwijl mutaties die het zonadhesinedomein
veranderen met name slechthorendheid van de hoge tonen veroorzaken (tabel).7 12
Verder blijken mutaties die een vervanging van cysteïne door een ander aminozuur
veroorzaken, samen te gaan met een progressief beloop van het gehoorverlies.12 In
figuur 2 zijn de gemiddelde audiogrammen van de beschreven families met niet-
progressieve middenfrequentieslechthorendheid weergegeven.
Het eiwit en het orgaan van Corti
Het TECTA-gen codeert voor ?-tectorine, dat de belangrijkste niet-collagene com-
ponent is van de tectoriale membraan in de cochlea en de otolietenmembraan in de
maculae van het vestibulaire systeem. In het ?-tectorine kan een aantal bekende
domeinen worden onderscheiden: het entactine G1-domein, het zonadhesine-
domein met "repeats" van de von-willebrand-factor type D en het zonapellucida-
domein.13
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Tabel 1. TECTA-genmutaties bij slechthorendheid type DFNA8/12 en kenmerken van het
betreffende fenotype. Mild gehoorverlies = 20-40 dB, matig ernstig 41-70 dB en ernstig = 71-
95 dB.
Land van
herkomst
Mutatie* Domein Leeftijd van
ontstaan
Fenotype Aangedaan Frequenties
Frankrijk7 C1619S ZA Variabel Mild tot matig ernstig Progressief Hoog
Zweden8 C1057S ZA Postlinguaal Mild tot ernstig Progressief Hoog
Turkije9 C1509G ZA Prelinguaal Mild tot matig ernstig Progressief Hoog
Spanje10 C1837G ZP Postlinguaal Mild tot matig ernstig Progressief Midden
Oostenrijk3 Y1870C ZP Prelinguaal Matig ernstig Stabiel Midden
België4 L1820F,
G1824D
ZP Prelinguaal Matig ernstig Stabiel Midden
Japan11 R2021H ZP Prelinguaal Mild tot matig ernstig Stabiel Midden
Nederland12 R1890C ZP Prelinguaal Mild tot matig ernstig Stabiel Midden
*"C1619S" betekent dat op plaats 1619 in het eiwit het aminozuur cysteïne (C) is vervangen door serine
(S); D = asparaginezuur; F = fenylalanine; G = glycine; H = histidine; L = leucine; R = arginine; Y =
tyrosine
Mutaties in het TECTA-gen die leiden tot de vervanging van een cysteïne door een
ander aminozuur of die leiden tot een extra cysteïne, veranderen wellicht de
zwavelbruggen in het ?-tectorine en daardoor de structuur. Samen met drie
verschillende typen collagenen en de twee andere niet-collagene glycoproteïnen ?-
tectorine en otogeline, vormt ?-tectorine de extracellulaire matrix van de tectoriale
membraan. De stereocilia van de buitenste haarcellen maken contact met de
tectoriale membraan, die van de binnenste haarcellen niet direct. De precieze
functie van de tectoriale membraan begint langzaam duidelijk te worden. Defecten
in deze membraan leiden tot gehoorverlies, zoals DFNA13 (COL11A2) en DFNA8/12.
Mutaties in COL11A2 leiden tot een abnormale type XI-collageen-?2-keten en
daardoor tot disorganisatie van de collageenfibril (of type II-collageen) in de
tectoriale membraan.
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Onderzoek aan muizenmodellen met een defect in het TECTA-gen heeft aangetoond
dat de tectoriale membraan essentieel is voor het positioneren van stereocilia van
de buitenste haarcellen, dusdanig dat een bepaalde frequentie in de betrokken regio
van de cochlea optimaal versterkt wordt.14 Ook werd duidelijk dat de tectoriale
membraan essentieel is voor de beweging van de basale membraan die ervoor zorgt
dat de binnenste haarcellen geactiveerd worden bij specifieke frequenties.14 Muizen
waarbij ?-tectorine ontbreekt, hebben een gehoorverlies van 35 dB. De structuur van
de tectoriale membraan is abnormaal en het ligt niet over het orgaan van Corti
heen. Otoakoestische emissies werden niet waargenomen bij deze muizen.5
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Figuur 2. Gemiddeld audiogram van de beschreven families met niet-progressieve
middenfrequentie slechthorendheid:??, Oostenrijk3; ? ?, België4; ------, Japan11;
——, Nederland12.
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De populatie
Binnen de patiëntenpopulatie van een kinderaudiologisch centrum is komvormig
perceptief gehoorverlies weliswaar zeldzaam, maar niet ongewoon. Bij een
belangrijk deel van de patiënten gaat het om een onverklaard geïsoleerd vóór-
komen. In de overige gevallen blijken meerdere familieleden aangedaan. Omdat een
hoortoestel niet steeds uitkomst brengt, blijft het gehoorverlies vaak voor de
omgeving verborgen. Het vóórkomen van komvormig gehoorverlies bij andere
familieleden valt daarom niet steeds op. Kleine families met meerdere aangedane
leden zijn bij een kinderaudiologisch centrum niet zeer zeldzaam. Wij schatten dat
er bij het Nijmeegs audiologisch centrum enkele tientallen families met deze
aandoening bekend zijn. Grote families met veel (10-15) aangedane leden zijn wel
tamelijk zeldzaam. Inmiddels is het gelukt om 4 families met meer dan 10 aan-
gedane personen in kaart te brengen. Met behulp van dergelijke families kan via
koppelingsonderzoek naar het type DFNA gezocht worden. Komvormig gehoor-
verlies kan, meer incidenteel dan systematisch zoals bij DFNA8/12, ook vóórkomen
bij DFNA13.
Diagnostiek
Audiometrisch onderzoek binnen een familie maakt duidelijk of er ook bij andere
familieleden komvormig perceptief gehoorverlies bestaat. Een autosomaal
dominante overerving kan daarmee aannemelijk worden. Mutatieanalyse van het
TECTA-gen wordt nog niet aangeboden als routine-DNA-diagnostiek. In het oto-
genetisch researchlaboratorium te Nijmegen is dit onderzoek wel mogelijk. Er is om
redenen van efficiëntie een voorkeur om bij voldoende omvang van de aangedane
familie koppelingsonderzoek voor de chromosomale regio van het TECTA-gen te
verrichten om vooraf te bevestigen dat het gaat om DFNA8/12. Dergelijk gen-
koppelingsonderzoek voor een familie kan in elk genetisch centrum uitgevoerd
worden. De Nijmeegse otogenetische researchgroep is, indien gewenst, bereid
vooraf het benodigde klinische familieonderzoek te verrichten.
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Abstract
A novel TECTA mutation,  p.R1890C,  was  found  in  a  Dutch  family  with  non-
syndromic autosomal dominant sensorineural hearing impairment. In early life,
presumably congenital, hearing impairment occurred in the midfrequency range,
amounting  to  about  40  dB  at  1  kHz.  Speech  recognition  was  good  with  all
phoneme recognition scores exceeding 90%. An intact horizontal vestibulo-ocular
reflex was found in four tested patients. The missense mutation is located in the
zona pellucida (ZP) domain of ?-tectorin. Mutations affecting the ZP domain of ?-
tectorin are significantly associated with midfrequency hearing impairment.
Substitutions affecting other amino acid residues than cysteines show a
significant association with hearing impairment without progression. Indeed, in
the present family progression seemed to be absent. In addition, the presently
identified mutation affecting the ZP domain resulted in a substantially lesser
degree of hearing impairment than was previously reported for DFNA8/12 traits
with mutations affecting the ZP domain of ?-tectorin.
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Introduction
Various phenotypes of autosomal dominant, sensorineural, nonsyndromic hearing
impairment can be distinguished. Up untill now, 54 loci have been mapped and 21
genes have been identified.1. The different gene loci for these nonsyndromic types of
hearing impairment have been designated DFN (DeaFNess) and are numbered in
chronological order of discovery. Autosomal dominant types are referred to as DFNA.
These types of hearing impairment can be characterised by age of onset, presence
and degree of progression, severity of hearing impairment and audiometric
configuration. One of these configurations is the “cookie-bite”, U-shaped or trough-
shaped audiometric configuration of midfrequency hearing impairment. This
phenotype can be found in DFNA8/12 (TECTA) and DFNA13 (COL11A2).1.
DFNA8/12 has been mapped to the chromosomal locus 11q22-242,3 and  is caused by
mutations in TECTA.4,5 This gene encodes ?-tectorin, the most important non-
collagenous component of the tectorial membrane in the cochlea and the otolith
membrane in the maculae of the vestibular system. The tectorial membrane
consists of an extracellular matrix overlying the organ of Corti that contacts the
outer cochlear hair cells and plays an important role in intracochlear sound
transmission by ensuring optimal cochlear feedback.6. Recently, Legan et al.7
described a second major role for the tectorial membrane. Neural tuning curves
relating to inner hair cell stimulation showed a remarkable loss in sensitivity in
mutant mice. This effect was attributed to a loss in coupling of the inner hair cell
bundles to tectorial membrane motion caused by enlargement of the subtectorial
space in the region of these hair cells.
In this study we report a Dutch family with nonprogressive, presumably prelingual,
midfrequency hearing impairment caused by a novel missense mutation affecting
the zona pellucida (ZP) domain of ?-tectorin. Statistical testing was performed by
using this mutation and the mutations previously identified to show the
significance of the association between the type of mutation and the respective
phenotype.
Patients and methods
A three-generation pedigree was established for the present family. Twenty-four
family members participated in this study. Their medical history was taken and
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otologic examination was performed. Nonhereditary causes of hearing loss were
excluded and written informed consent was obtained. All individuals included in this
study underwent pure tone audiometry; speech audiometry was only performed in
affected persons. Vestibular function was tested in four patients. Blood samples
were obtained for linkage analysis from 11 affected and 13 unaffected family
members.
Audiometric analysis
Pure tone and speech audiometry were performed in a sound treated room,
conforming to the International Standards Organisation (ISO) standards.8,9 The
individual 95th percentile threshold values of presbyacusis (P95)  in  relation  to  the
patient’s  sex  and  age  were  derived  for  each  frequency  by  using  the  ISO  7029
method.10 Individuals were considered affected if the best hearing ear showed
thresholds beyond the P95.
Speech audiometry
Speech audiometry was performed in a quiet environment using standard
monosyllabic Dutch word lists. The maximum monaural phoneme score (% correct
recognition) was derived from a performance vs. intensity plot.
Vestibulo-ocular examination
Vestibulo-ocular responses were evaluated in four patients (aged 23, 39, 43 and 45
years) by using electronystagmography (in the dark with open eyes) with computer
analysis as previously described.11 The horizontal vestibulo-ocular reflex (VOR) was
evaluated by performing velocity-step tests at 90º/s. Ocular motor evaluation
comprised saccades, smooth pursuit eye movements and optokinetic nystagmus, as
well as gaze-evoked and spontaneous nystagmus.
Genotyping
DNA from lymphocytes was isolated as described by Miller et al.12 Polymorphic
microsatellite markers were amplified by using 50 ng genomic DNA in 20 mM Tris-
HCl (pH 8.4),  50 mM KCl,  1.5 mM MgCl2, 2 U Taq Polymerase (Invitrogen, Breda, the
Netherlands), 125 µM dATP, 125 µM dGTP, 125 µM dTTP, 1.5 µM dCTP, 400 nM 32P-
dCTP (111 TBq/mmol; MP Biomedicals, Irvine, CA, USA), 2.7 ng forward primer, and 2.7
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ng reverse primer in a total volume of 25 µl. PCR products were analysed as
described by Kremer et al.13
Linkage analysis
Two-point lod scores and the maximum lod score were calculated with the Mlink
and Ilink subroutines, respectively, of the LINKAGE programme (version 5.1).14,15 Full
penetrance was assumed and the disease allele frequency was set at 0.0001. The
phenocopy rate was estimated to be 1 in 1,000.
Mutation analysis
Primer sequences and conditions for amplification of all exons of TECTA (GenBank ID
NM_005422.1) are available on request. PCR products were sequenced by using the
ABI PRISM BigDye Terminator Cycle Sequencing V2.0 Ready Reaction Kit and
analysed with the ABI PRISM 3730 DNA analyser (Applied Biosystems, Foster City, CA,
USA). Of the last exon, 450 nucleotides of the 3’-untranslated region were analysed.
Segregation  in  the  family  and  presence  of  the  c.248C>T  nucleotide  change  in  165
controls was tested by amplification of exon 3 and subsequent digestion with NlaIII
according to the manufacturer’s protocols (Invitrogen). Segregation in the family
and presence of the nucleotide substitution, c.5668C>T, in 184 controls was tested by
amplification of exon 18 and subsequent digestion with BsgI according to the
manufacturer’s protocols (Invitrogen).
Data analysis
Binaural mean threshold levels were used to perform cross-sectional linear
regression analysis (threshold on age) at each frequency. The presence/absence of
progression was assessed by testing whether or not the 95% confidence interval for
the regression coefficient (slope) included zero. Phoneme recognition scores
(binaural mean) were plotted against the degree of impairment, expressed as the
binaural mean pure tone average (PTA) at the frequencies 1, 2 and 4 kHz (PTA 1, 2, 4 kHz).
Curve fitting in this performance-impairment plot was conducted according to a
previously reported method using a sigmoidal equation with variable slope.16 A
previously described group of subjects with only presbyacusis17 was  used  as  a
reference group. Only those subjects with presbyacusis who had a matching degree
of impairment by PTA 1,  2,  4  kHz were used for statistical testing. A 2 x 2 contingency
table  was  constructed  by  using  one  of  the  fitted  curves  as  a  dividing  line  for
dichotomising the speech recognition scores in both groups and Fisher’s exact test
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was  performed.  Contingency  tables  (2  x  2)  were  also  used  to  test  for  the  possible
significance (p < 0.05 in Fisher’s exact test) of associations between genotype and
phenotype features.
Results
The pedigree (Figure 1) comprised three generations and included 14 affected family
members (8 males and 6 females), 11 of whom were still alive and willing to
participate in this study. The pattern of inheritance is autosomal dominant.
Figure  1.   Pedigree  and  chromosome  11  haplotypes  of  the  family.  The  at-risk  haplotype  is
indicated by the black bar. If the phase is unknown, the haplotype is marked with a thin line.
Brackets indicate deduced marker alleles. The marker order is according to the Human
Genome Working Draft May 2004 and corresponds to the deCODE genetic map.18
There was no evidence of any other cause of hearing impairment, except for one
patient who had undergone stapes replacing surgery for unilateral otosclerosis. This
patient was included in the present study by only using audiometric data from her
other ear.  The first symptoms of hearing impairment were reported at ages ranging
from <1 to 30 years. Vestibular symptoms were not reported. Otoscopy was normal
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in all persons except the patient mentioned above. Pure tone audiograms (Figure 2)
were symmetric and often showed a so-called cookie-bite shape, which indicates
that predominantly the middle frequencies are affected. The highest threshold was
most often found at 1 kHz, followed by 2 kHz. It was usually in the range of 40-60 dB,
apparently independent of age.
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Figure 2. Binaural mean air conduction thresholds of the affected family members shown in
audiogram format. Numbers designate age in years. Dotted line represents P50 thresholds
for  the  last  age  >20  years  according  to  ISO  7029.10 The  panels  are  ordered  by  age  at  last
complete audiogram.
Audiometric analysis
All available cross-sectional data, combining individual longitudinal measurements
(seven cases), i.e. only those pertaining to the patient’s last complete audiogram,
and single-snapshot measurements (four cases) are shown for the separate
frequencies in figure 3.
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Figure 3. Cross-sectional linear regression analysis of the patient’s binaural mean thresholds
at 0.25-8 kHz, as measured in the last complete audiological test. Numbers designate age in
years.
We found only shallow positive or negative slopes. Indeed, the 95% confidence
interval for the slope of the regression line included zero at all frequencies. Thus, it
appeared that the thresholds did not depend on age. Age could therefore be ignored
and mean thresholds covering all ages were calculated (Figure 4).
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Figure 4. Mean threshold ± 1 across-subjects SD for the present family (open circles and fat
solid line). Mean thresholds for previously reported nonprogressive DFNA8/12 traits are
included:??, Kirschhofer et al.2;? ?, Govaerts et al.5; ------, Iwasaki et al.19.
Figure 4 includes the mean evaluable thresholds previously reported for other
DFNA8/12 families with nonprogressive hearing loss.2,5,19 Remarkably, the mean
threshold for the present family is substantially lower than the mean threshold of
any of the other families. The difference amounts to 20-30 dB. The previously
described families showed a tendency for a maximum threshold at 2 kHz rather than
1 kHz in the present family.
Speech recognition
All of the present patients had maximum phoneme recognition scores of  >90% at a
PTA1,2,4 kHz of 60 dB or better (Figure 5). The presbyacusis data used as a reference
were matched by selecting the subjects with a PTA1,2,4 kHz of 60 dB or better. Fischer’s
exact test indicated a significant difference in favour of the present patients
(p=0.018 or 0.034, depending on the dividing line). As can be read from the fitted
curves, the difference amounted to about 10-15% on average at a PTA1, 2, 4 kHz close to
60 dB (Figure 5).
 .25  .5 1 2 4 8
-10
0
100
80
40
20
120
60
kHz
dB HL
Dutch DFNA8/12 (TECTA) family
56
10 20 30 40 50 60
0
20
40
60
80
100
                           PTA1,2,4 kHz (dB HL)
   
   
   
   
   
 %
R
ec
og
ni
tio
n
Figure 5. Binaural mean phoneme recognition score (% correct) plotted against binaural
mean PTA1,2,4 kHz for patients of the present family (open circles and bold solid line) and for a
group of subjects with presbyacusis showing a matching degree of impairment (crosses and
thin solid line13).
Vestibulo-ocular examination
None of the patients had any vestibular symptoms. Ocular motor tests were normal
in the four patients tested. Intact vestibular function was found with a normal
horizontal VOR gain in all of these patients, with an abnormally long dominant VOR
time constant in two of them.
Linkage analysis
The two DFNA loci associated with midfrequency hearing impairment, DFNA8/12
and DFNA13, were tested for linkage with polymorphic markers flanking or within
the causative genes TECTA and COL11A2, respectively. For the DFNA8/12 locus,
linkage was detected with a maximum lod score of 4.00 (? = 0.0) for the intragenic
marker  D11S4167.  The  DFNA13  locus  was  excluded  (lod  score  <-2.0)  by  using  the
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markers D6S1666, D6S273, D6S276, and D6S1615. The at-risk haplotype, which
includes the DFNA8/12 locus on chromosome 11, is depicted in figure 1.
DNA sequencing of TECTA
DFNA8/12 is caused by missense mutations in TECTA. We analysed TECTA for
mutations in all 23 exons and intron-exon boundaries in family member III-11. Both
the forward and reversed DNA sequence of exon 3 showed a nucleotide change
(c.248C>T)  that  is  predicted  to  result  in  the  substitution  of  a  methionine  for  a
threonine at position 83 (Figure 6A).
Figure 6. Nucleotide changes in exon 3 and exon 18 of TECTA. Chromatograms showing the
c.248C>T  transversion  in  exon  3  in  individual  III:11  (A),  and  the  normal  DNA  sequence  in  a
healthy individual (B). Chromatograms showing the c.5668C>T transversion in exon 18
individual III:11 (C), and the normal DNA sequence in a healthy individual (D).
This novel variant removes an NlaIII restriction site. The substitution segregated
with the disease and was not present in 330 alleles from healthy controls as
determined by restriction analysis (data not shown). In addition, another change,
c.5668C>T, was detected that is predicted to result in the substitution of a cysteine
for an arginine at position 1890 in the ZP domain of ?-tectorin (Figure 6C). This
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change creates a BsgI restriction site, segregated with the disease and was not
present in 368 alleles from healthy controls (data not shown).
Finally, four known single nucleotide polymorphisms (rs612969, rs536069, rs520805,
and rs586473; www.ncbi.nlm.nih.gov/SNP) were identified in family member III-11.
Genotype-phenotype correlation
Alpha-Tectorin is composed of three distinct modules: the entactin G1 domain, the
zonadhesin (ZA) domain with von Willebrand factor type D repeats, and the ZP
domain.20 Mutations affecting the ZP domain are associated with midfrequency
hearing impairment, whereas mutations in the ZA domain are associated with
hearing impairment primarily affecting the high frequencies (table 1).2,4,5,19,21-24
Hearing impairment can range from mild to severe and has prelingual or postlingual
onset. Furthermore, mutations causing substitution of cysteine residues are
associated with progressive hearing impairment.
Table 1: DFNA8/12 TECTA mutations and the associated phenotypes
Origin Mutation Exon Domain Onset Phenotype* Frequency
French21 C1619S 14 ZA Variable Mild to moderate-severe, progressive High
Swedish22 C1057S 10 ZA Postlingual Mild to severe, progressive High
Turkish23 C1509G 13 ZA Prelingual Mild to moderate, progressive High
Spanish24 C1837G 17 ZP Postlingual Mild to moderate, progressive Mid
Austrian2 Y1870C 18 ZP Prelingual Moderate, stable Mid
Belgian4-5 L1820F
G1824D
17 ZP Prelingual Moderate, stable Mid
Japanese19 R2021H 20 ZP Prelingual Mild to moderate, stable Mid
Dutch R1890C 18 ZP Prelingual Mild to moderate, stable Mid
*According to the GENDEAF criteria: mild, 20-40 dB; moderate, 41-70 dB; severe, 71-95 dB.25
Two-by-two contingency tables were used for testing the possible significance (p
<0.05 in Fisher’s exact test) of associations between the position and nature of the
amino acid substitutions and the specific phenotypic features (table 2).
Mutations in the ZP domain are significantly associated with midfrequency hearing
impairment, whereas mutations in the ZA domain are associated with high
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frequency hearing loss (p=0.018). Cysteine replacing mutations are associated with
progressive hearing impairment (p=0.014).
Table 2: Two-by-two contigency showing association between the type of mutation (geno-
type) and the phenotype. Values within parentheses pertain to the number of observations
prior to the inclusion of the present study.
A
Affected domain Mid frequency type High frequency type
ZP 5 (4) 0
ZA 0 3
Fisher’s exact test: p=0.018 (0.029).
B
C-any substitution Stable Progressive
Yes 0 4
No 4 (3) 0
Fisher’s exact test: p=0.014 (0.029).
Discussion
Two changes, p.R1890C and p.T83M, were detected in ?-tectorin in a family with
autosomal dominant midfrequency hearing impairment. The mutation p.R1890C is
present in the ZP domain of ?-tectorin,  whereas  p.T83M  is  not  found  in  a  specific
domain. Both amino acid residues are conserved among human, rat, and chicken ?-
tectorin. The identity between these three orthologs is higher than 70%. Considering
the phenotype and the position of the mutation, p.R1890C is likely to be causative
for hearing impairment in the family under study, because cysteines in the ZP
domain are involved in the intra- and/or intermolecular interactions of ?-tectorin,
and mutations of cysteines or other amino acid residues into cysteines have been
shown to cause autosomal dominant hearing impairment, due to problems with ?-
tectorin secretion.26 Also, the p.T83M change seems to be a relatively mild amino
acid substitution according to the Dayhoff table.27 The nucleotide change is not
predicted to affect splicing of the TECTA mRNA. However, because this change was
not present in controls, it can not be excluded that it has an effect on the phenotype
of these patients or it may even act synergistically with the p.R1890C mutation.
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It has been suggested in a previous report that patients with TECTA-based mid-
frequency hearing impairment might be less prone to presbyacusis because they are
generally exposed to lower-than-usual levels of sound energy at the level of the
organ of Corti.2 Unaided phoneme recognition scores were all > 90% and proved to
be significantly higher than scores found in a reference group of patients with
presbyacusis. The difference amounted to 10-15% at around a PTA1, 2, 4 kHz of 60 dB. It
is likely that this difference in favour of the present patients relates to the fact that
they have substantially better thresholds at higher frequencies than the subjects
with presbyacusis. If a protective effect against presbyacusis indeed occurs, it might
be less important in the present family, given the observation that the threshold
levels at 4-8 kHz were about 20-30 dB, whereas they amounted to 40-60 dB in the
previously reported families (Figure 4). Nevertheless, we have attempted to
substantiate the presence of any such protective effect by correcting the individual
thresholds at each frequency for the median (P50) threshold indicated by ISO 7029.10
Linear regression analysis (threshold on age) similar to the one illustrated in figure 3
performed on the corrected thresholds produced plots with regression lines that
mainly showed negative slopes. However, none of these slopes was significantly
negative  (data  not  shown)  and  thus  did  not  support  any  hypotheses  about
protection from presbyacusis.
Differences in phenotype among DFNA8/12 families appear to be related to the
position of the mutations in either the ZP or ZA domain of ?-tectorin as well as the
nature of the amino acid substitution (Table 1). Mutations in the ZP and ZA domains
have been related to midfrequency and high frequency hearing impairment,
respectively.2,4,5,19,21-24 Substitutions replacing cysteines have been implicated in
progressive hearing impairment.21-24  There are now sufficient observations to show
the significance of these genotype-phenotype correlations (Table 2A, B).
There is a significant association between mutations affecting the ZP domain and
the midfrequency impairment phenotype as well as between mutations affecting
the ZA domain and the high frequency impairment phenotype (Table 2A). There is
also a significant association between mutations causing cysteine-replacing
substitutions and age-related progression of the hearing impairment (Table 2B). It
should be noted that the level of significance (0.05 as usual) might be adjusted for
multiple testing as two independent tests were performed with the same material.
This would require the p value to be <0.0253 instead of <0.05. In Table 2, the p values
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fulfilled this requirement; however, the collective data prior to the inclusion of the
present family (values in parentheses in Table 2A, B) did not. Thus, the data on
TECTA genotypes and the corresponding phenotypes support the previously
suggested associations on the basis of significant test results.
In the four patients, we found an intact horizontal VOR. Goodyear and Richardson28
found abundant expression of ?-tectorin in utricular and saccular otoconial
membrane, not in the crista ampullaris. Legan et al6 found substantially reduced
otoconial membranes with only a few, abnormally large, scattered otoconia in mice
homozygous for a targeted deletion in ?-tectorin; the cupulae in the semicircular
canals were normal. These mice did not show any spontaneous vestibular
behavioural deficit, such as circling or head bobbing. However, no righting or
swimming tests were performed. The present finding that the horizontal VOR was
intact in the present patients conforms with the previous finding of Iwasaki et al.19,
i.e. the only other study in which  vestibular testing was performed. However,
otolith reflexes are not covered by the type of vestibular testing performed. A
suggestive anamnestic finding was reported for a French family whose three
affected members had started walking only at 24 months of age.21  Vestibular
testing was not performed in this family. It seems that the question as to whether
DFNA8/12 patients have normal or abnormal otolith reflexes still requires
appropriate instrumental otolith-testing paradigms. Given the type of
histopathology observed in animal models for TECTA6, imaging of the inner ear
cannot be expected to contribute to the knowledgepool as yet. Indeed, no abnormal
scanning results have been obtained up to now.
In summary, we identified a novel mutation, p.R1890C, in the ZP domain of ?-
tectorin in a family with a somewhat milder degree of midfrequency hearing
impairment than previously reported to be associated with mutations in this
domain. Statistical tests on genotype-phenotype correlations of the present and
collective data on DFNA8/12 have now revealed a significant association between
the affected ?-tectorin domain (ZP or ZA) and the type of hearing impairment (mid-
frequency or high frequency type), as well as a significant association between a
cysteine-replacing substitution and age-related progression in hearing impairment.
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Abstract
In DFNA8/12, an autosomal dominantly inherited type of nonsyndromic hearing
impairment, the TECTA gene mutation causes a defect in the structure of the
tectorial membrane in the inner ear. Because DFNA8/12 affects the tectorial
membrane, patients with DFNA8/12 may show specific audiometric
characteristics. In this study, five selected members of a Dutch DFNA8/12 family
with a TECTA  sensorineural hearing impairment were evaluated with pure-tone
audiometry, loudness scaling, speech perception in quiet and noise, difference
limen for frequency, acoustic reflexes, otoacoustic emissions, and gap detection.
Four out of five subjects showed an elevation of pure tone thresholds, acoustic
reflex thresholds, and loudness discomfort levels. Loudness growth curves are
parallel to those found in normal hearing. Suprathreshold measures such as
difference limen for frequency modulated pure tones, gap detection, and
particularly speech perception in noise are within the normal range. Distortion
otoacoustic emissions are present at the higher stimulus level. These results are
similar to those previously obtained from a Dutch DFNA13 family with mid-
frequency sensorineural hearing impairment. It seems that a defect in the
tectorial membrane results primarily in an attenuation of sound, whereas
suprathreshold measures, such as otoacoustic emissions and speech perception in
noise, are preserved rather well. The main effect of the defects is a shift in the
operation point of the outer hair cells with near intact functioning at high levels.
As most test results reflect those found in middle-ear conductive loss in both
families the sensorineural hearing impairment may be characterized as a cochlear
conductive hearing impairment.
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Introduction
Since 1992, more than 100 types of sensorineural, nonsyndromic hearing
impairment have been identified.1 The different chromosomal loci for non-
syndromic types of hearing impairment have been designated DFN (DeaFNess) and
are numbered in chronological order of discovery. Autosomal dominant types are
referred to as DFNA, autosomal recessive types as DFNB, and X-linked types as DFN.
These types of hearing impairment can be characterised by age of onset, presence
and degree of progression, severity of hearing impairment, and audiometric
configuration.2 One of these configurations is the U-shaped or “cookie-bite”
audiometric configuration of midfrequency hearing impairment that can be found
in DFNA8/12 (TECTA) and DFNA13 (COL11A2).1
The first descriptions of autosomal dominant midfrequency hearing impairment
relate to an Austrian (DFNA8) and a Belgian (DFNA12) family.3,4 The original proposed
linkage to chromosome 15q in the Austrian family was later on withdrawn and
relocated to chromosome 11q22-24.3-5 When the mutations proved to be in the same
gene (TECTA), which encodes alpha-tectorin, the locus was redesignated DFNA8/12.6
Alpha-Tectorin is an important noncollagenous component of the tectorial
membrane in the cochlea and its level of expression is high during tectorial
membrane morphogenesis, between the 12th and 20th week of embryonic
development, after which it decreases dramatically.7 The tectorial membrane
consists of an extracellular matrix overlying the organ of Corti that contacts the
outer hair cells and plays an important role in intracochlear sound transmission by
ensuring optimal cochlear feedback.8 Research on transgenic mice showed that the
tectorial membrane facilitates the motion of the basilar membrane to optimally
drive the inner hair cells.9 The alpha-tectorin protein comprises three distinct
modules: the entactin G1 domain, the zonadhesin (ZA) domain, and the zona
pellucida (ZP) domain.10 Mutations affecting the ZP domain are significantly
associated with midfrequency hearing impairment, whereas mutations in the ZA
domain are significantly associated with high frequency hearing impairment.11
Furthermore, mutations in either domain causing substitution of cysteine residues
are significantly associated with progressive hearing impairment11.
Legan et al. studied mice with a mutation in the ZP domain of TECTA.9 In these mice
with  a  heterozygous  Y1870C  mutation  (TectaY1870C/+), the tectorial membrane’s
matrix structure is disrupted and its adhesion zone is reduced in thickness.9 These
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changes do not seriously influence the tectorial membrane’s role in ensuring
optimal cochlear feedback; however, neural tuning is broadened and a decrease in
sensitivity is observed at the tip of the neural tuning curve.9
In 2003, De Leenheer et al. studied the audiological characteristics of affected
members of a Dutch DFNA13 family.12 DFNA13  is  another  type  of  autosomal
dominant midfrequency hearing impairment, which is caused by a mutation of
COL11A2 on chromosome 6p that also results in alterations of the tectorial
membrane.13 In this DFNA13 family, hearing impairment was nonprogressive.12 They
observed that in younger subjects suprathreshold signal analyzing capacities are not
compromised by the moderate sensorineural hearing impairment, and concluded
that DFNA13 results in a cochlear type of conductive hearing impairment.12
In the present DFNA8/12 (TECTA) family nonprogressive midfrequency hearing
impairment is caused by a missense mutation substituting arginine residues
(R1890C) in the ZP domain of alpha-tectorin.11 The presumably congenital hearing
impairment predominantly affects the mid frequencies (1 and 2 kHz), with
thresholds around 40 dB.  Speech recognition was almost perfect with phoneme
recognition scores higher than 90%.11
Such patients with a proven and specific defect in the tectorial membrane provide a
unique opportunity to study the audiometric characteristics of tectorial membrane
defects. To further outline the audiometric phenotype of DFNA8/12, an extended set
of  audiological  tests  was  performed  on  selected  affected  members  of  a  Dutch
DFNA8/12 (TECTA) family. As the tectorial membrane is essential both in cochlear
transduction and amplification tests were selected that focus on suprathreshold
chacteristics in the time and frequency domain. Outer hair cell functionality was
tested separately with distortion product otoacoustic emissions (DPOAE). The results
of  these  tests  will  be  compared  to  those  previously  obtained  from  members  of  a
Dutch DFNA13 (COL11A2) family.12
Methods and material
Five adult members of the Dutch DFNA8/12 (TECTA) family, all with a confirmed
TECTA gene mutation, were contacted and agreed to participate in this study.11 The
gene expression was not significantly different for male and female family
members. Subjects participating in this study are indicated as A, B, C, D and E in the
Chapter 2.3
69
pedigree shown in Figure 1. Subjects A to D showed hearing impairment typical for
the disorder; subject E only has a relatively mild degree of hearing impairment, but
was nevertheless included. Measurements were performed on the ear with the
greatest overall impairment.
Figure 1. Pedigree of the Dutch DFNA8/12 (TECTA) family. Subjects participating in this study
are indicated as (A), (B), (C), (D) and (E).11
At the beginning of the experiment pure-tone thresholds were measured with
standard audiometric procedures and equipment (Interacoustics AC-40 audiometer).
In addition, loudness discomfort levels were measured to provide safe upper limits
of stimulus levels when measuring acoustic reflexes. Speech perception was
measured in quiet with standard monosyllabic Dutch word lists.14 Each list consists
of 11 CVC syllables and scores are based on correct repetition of phonemes.
Ipsilateral acoustic reflexes were measured at the pressure providing maximum
compliance in the tympanogram (Madsen Zodiac 901 tympanometer).
DPOAE were measured with ILO 292 equipment. The stimuli had a frequency ratio of
1.2, and stimulus levels of 75/60 and 80/70 dB SPL were used. At these levels,
artifacts due to nonlinearities in the measurement setup fell below the noise floor.
Loudness scaling was performed with a 7-point categorical scale at 500 Hz and 2000
Hz.15 Gap detection was measured with gated white noise and with 500-Hz and 2-
kHz noise. Digital filtering of the temporal pattern created the frequency-specific
stimuli.
A
E
B
D
C
Audiological evaluation of DFNA8/12 (TECTA)
70
Frequency discrimination was measured with frequency-modulated pure tones
generated by an audiometer (Interacoustics AC-40). The modulation frequency
ranged between 0.1% and 5%. Subjects indicated whether their pitch percept was
stable (not modulated) or unstable (modulated). At least three trials aiming at 50%
correct performance with a sqrt(2) step size were used. Stimuli were presented at
the individual listener’s most comfortable level, i.e. about 40 dB SL.
Speech perception in noise was measured with short, everyday Dutch sentences.16
The speech reception threshold (SRT) was measured with the simple up-down
procedure proposed by Plomp and Mimpen.16 SRT will be expressed as a signal-to-
noise ratio. All tests were performed in a double-walled sound-treated room. Data
will be compared to those for young normal-hearing (NH) listeners.
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Figure 2. Individual hearing thresholds and loudness discomfort levels for subjects (A-E). Air
conduction thresholds are indicated with open squares (right ear) and triangles (left ear),
and loudness discomfort levels are indicated with black squares (right ear) and triangles
(left ear).
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Results
Figure 2 shows pure-tone thresholds and loudness discomfort levels on an individual
basis. No substantial air-bone gaps were observed. Subjects are ordered according to
their age. All subjects exhibited a hearing impairment between 1 and 4 kHz ranging
from about 30 to 60 dB. In all subjects loudness discomfort levels appeared higher
than normal.17 Acoustic reflex thresholds obtained with ipsilateral stimulation are
shown in Table 1. Most reflex thresholds are elevated compared to the value of 85 dB
HL for normal hearing.18
Table 1. Acoustic reflex thresholds in dB HL for ipsilateral stimulation (worst ear) with pure-
tone stimuli of 0.5, 1, 2, and 4 kHz.
Subject 0.5 kHz 1 kHz 2 kHz 4 kHz
A 100 100 105 >100
B 80 90 90 100
C 85 95 95 100
D 85 95 95 95
E 90 95 95 100
The occurrence of DPOAE is shown in Table 2. In subject A no emissions were
measured. At stimulus levels of 80/70 dB SPL emissions were found in the other four
subjects;  at  the  lower  stimulus  level  of  75/60  dB  SPL,  some  emissions  occurred  in
subjects B-D. Interestingly, in subject E, who has the most favourable pure-tone
thresholds, no emissions occurred at the lowest stimulus level.
Table 2. Distortion product emission (DPOAE) data with 75/60 and 80/70 dB SPL stimuli,
measured with ILO-92 equipment (worst ear). Emissions were tested at 1.0, 1.4, 2.0, 2.8, 4.0,
and 6.0 kHz. The frequency range at which emissions occur is indicated for each subject.
Subject DPOAE (75/60) DPOAE (80/70)
A n.a. n.a.
B 4.0 kHz 2.0-6.0 kHz
C 1.0, 2.8, 4.0 kHz 1.0-6.0 kHz
D 1.4, 4.0 kHz 1.0-6.0 kHz
E n.a. 1.0-6.0 kHz
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Figure 3. Loudness growth functions obtained from the worst ear with 7-point categorical
scaling (modified Würzburger Hörfeld Skalierung) for 500-Hz and 2-kHz stimuli. Open circles
represent scores for subjects (A-D). Scores for subject (E) are represented by black dots.
Figure 3 shows loudness growth functions for 500-Hz and 2-kHz pure-tone stimuli,
obtained with a 7-point categorical scale.15 With the exception of the data for
subject E, loudness growth curves are more or less parallel to those for NH subjects,
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with elevated loudness discomfort levels between 100 and 120 dB HL. Loudness
judgments of subject E are within normal limits.
Gap detection was measured with 500-Hz and 2-kHz octave-bands of white noise,
and  with  unfiltered  white  noise.  Results  are  shown  in  Figure  4,  together  with
average data for seven naive NH listeners. The measurement for subjects A-D are
close to those of NH subjects, with a possible exception for subject D only at 500 Hz.
Subject E showed poor results at 500 Hz in this test.
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Figure 4. Gap detection with white noise and with 500-Hz and 2-kHz octave bands of noise.
Data are shown for subjects (A-E) (worst ear) and for normal-hearing listeners (NH).
Frequency discrimination as expressed in the Difference Limen for frequency (DLf)
was measured at 500 Hz and 2 kHz. Data are shown in Figure 5, together with data
for normal hearing.  The data of subjects A-D, except for the 2-kHz data in subject A,
are close to those of the normal subjects. Again, subject E performed relatively
poorly on this test.
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Figure  5.  Difference  Limen for  frequency  measured with  FM-modulated 500-Hz and 2-kHz
stimuli. Data are shown for subjects (A-E) (worst ear) and for normal-hearing (NH) listeners.
All subjects, with the exception of subject A, had a maximum score of 100% for
speech  perception  in  quiet  (data  not  shown).  Figure  6  shows  SRT  in  noise  for
sentences. The SRTs are expressed as a signal-to-noise ratio. The data for subjects A-
D are within the range of NH subjects (normal limit: -3 dB).16 Alternatively, when
expressing the data in Plomp’s D (distortion) term values of +2.4, +0.3, +0.9, +1.1 dB
are found for subjects A-D, respectively, and +5.1 dB for subject E. Once more, the
data for subject E are outside the normal range.
Discussion
Subjects A to D show an elevation of pure-tone thresholds, acoustic reflex
thresholds, and loudness discomfort levels. Loudness growth curves are parallel to
those found in normal hearing. Suprathreshold measures such as DLf, gap detection,
and particularly speech perception in noise are within the normal range. Distortion
otoacoustic emissions are present at the higher stimulus level. These findings
suggest normal cochlear function at higher stimulus levels. This contrasts strongly
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to results normally found in sensorineural hearing impairment resulting from loss of
outer and/or inner hair cells (e.g., presbyacusis, noise induced hearing loss).19.
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Figure 6. Speech Reception Thresholds in noise for sentences. Data are shown for subjects
(A-E) (worst ear) and for normal-hearing (NH) listeners.
We have no explanation for the relatively poor results found in subject E, whereas
his pure-tone thresholds were the most favorable (Figure 2). The hearing
characteristics of subject E resemble more closely sensorineural impairment due to
hair cell loss. Subject E is thus clearly breaking the trend set by subjects A to D. In
view of the unexpected degree of variation in findings, one might wish to extend
the number of reliable observations. Unfortunately, this is not an option for the
present family. However, the affected family members that were as yet too young to
include in this study may be examined later. Alternatively, additional families with a
similar phenotype may be recruited for new studies.
It emerges from the present study that a defect in the tectorial membrane reduces
sound transduction, resulting in sound attenuation. Suprathreshold measures, such
as otoacoustic emissions and speech perception in noise seem to be preserved
rather well. The preservation of stimulus fine structure at higher levels is also found
in conductive middle ear hearing impairment. This supports the conclusion of De
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Leenheer et al. that a conductive cochlear type of hearing impairment occurs in
tectorial membrane dysfunction.12
The changes observed in the TectaY1870C/+ mouse do not seriously influence the
tectorial membrane’s role in ensuring optimal cochlear feedback; however, neural
thresholds were elevated and neural tuning curves were broadened.9 Except for the
broadening of the neural tuning curves, this TectaY1870C/+ mouse model closely
represents the findings in our family. In humans, however, TECTA mostly affects
threshold sensitivity with little suprathreshold consequences.
The  test  results  of  our  subjects  are  quite  similar  to  the  results  in  subjects  with
DFNA13 (COL11A2).12 Mice with a targeted disruption of COL11A2 exhibit a loss of
organization of the collagen fibrils present in the tectorial membrane, causing
pathological alteration in structure of the tectorial membrane that reduces efficacy
of the outer hair cells, resulting in congenital hearing impairment that varies in
degree from mild to moderately severe.13 More  data  are  needed  on  the
suprathreshold hearing characteristics of COL11A2 mice.
In  recent  years,  mouse  models  provided  a  lot  of  insight  in  the  function  of  the
tectorial membrane and the basis of these types of autosomal dominant mid-
frequency hearing impairment.9-10,13 However, the exact mechanism of mutations
altering protein interactions and thus influencing the mechanotransductional
properties of the tectorial membrane remains uncertain.
In conclusion, the cochlear loss observed in selected members of a DFNA8/12 family
acts purely as an attenuation, a result of a reduced efficiency in the coupling of the
outer hair cells and the tectorial membrane. These findings are in line with previous
observations in DFNA13.12 Although the underlying mutations have different effects
on the structure of the tectorial membrane, the common effect of either disorder
may be characterised as a cochlear conductive hearing impairment. More precise
consequences of TECTA can only be stated with more certainty after studying
affected human temporal bones.
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Usher syndrome type III (USH3)

3.1
Serial audiometry and speech recognition findings
in Finnish Usher syndrome type III patients
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Abstract
Audiometric features, evaluated by serial pure tone audiometry and speech
recognition tests (n=31), were analysed in 59 Finnish Usher syndrome type III
patients with Finmajor/Finmajor (n=55) and Finmajor/Finminor (n=4) USH3A
mutations. These patients showed a highly variable type and degree of
progressive sensorineural hearing impairment: from normal to moderate USH2A-
like hearing impairment at young ages to profound or even USH1B-like hearing
impairment at more advanced ages. Compound heterozygous patients generally
showed a milder phenotype. The highest progression was seen during the first
two decades of life, gradually slowing down with further ageing. This type of
nonlinear progression may be unique amongst the Usher syndromes. Speech
recognition started to deteriorate at highly variable ages. In some patients, it
jeopardised normal speech and language development, whereas in others it was
still remarkably good at advanced ages.
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Introduction
Usher syndrome, an eponym of the Scottish ophthalmologist Charles Usher (1865-
1942), is an autosomal recessive disorder that is characterised by the combination of
sensorineural hearing impairment (SNHI) and progressive retinitis pigmentosa (RP).1
Some Usher syndrome patients also have vestibular dysfunction. The exact
prevalence  of  Usher  syndrome  is  still  unclear.  Estimates  range  from  3.5  to  6.2  per
100,000, making it the most common cause of deaf-blindness worldwide.2 In 1977,
Davenport and Omenn introduced a clinical classification of Usher syndrome and
after several modifications it now comprises three different types (I-III).3
Usher syndrome type I (USH1) is characterised by congenital, profound SNHI, RP and
vestibular areflexia. Until now, 7 chromosomal loci have been identified for USH1
(USH1A-G). Usher syndrome type II (USH2) shows a moderate-to-severe congenital
highfrequency SNHI, RP and intact vestibular responses. Three loci have been
identified for USH2 (USH2A-C). Usher syndrome type III (USH3) generally shows
postlingual, progressive SNHI, RP and variable vestibular responses. Only one locus
has been identified: USH3. At present, 7 genes (USH1B/MYO7A, USH1C/USH1C,
USH1D/CDH23, USH1F/PCDH15, USH1G/SANS, USH2A/USH2A, USH3/USH3A) have
been cloned.4 The genetic subtypes USH1B and USH2A account for about 75-80% of
all Usher patients worldwide, whereas USH3 is rare.5
In 1989 Karjalainen et al.6 reported a remarkably high prevalence of progressive
hearing impairment in Usher syndrome patients in Finland. After a nationwide
study, Pakarinen et al.7 concluded that USH3 accounts for 40% of all Finnish Usher
patients and therefore is the most common form of Usher syndrome in Finland. This
can be understood by taking notion of the Finnish disease heritage being the
consequence of the Finnish population history, which is characterised by the
presence of national and regional isolates with rapid expansion.8 Some mutations
have been enriched all over the country and probably have been imported by early
immigrants to Finland.9 The associated Finnish founder mutation identified in
nearly all USH3 cases is the Finmajor (c.300 T>G; c.528 T>G according to the new
nomenclature) mutation in the USH3A gene on chromosome 3q21-q25 that changes
a tyrosine into a premature stop codon (Y100X; now Y176X) and, when homozygous,
leads to a truncated protein.10,11 The  change  in  nomenclature  is  the  result  of  a
newfound exon, discovered in 2002 by Adato et al. Another associated mutation is
the Finminor (c.131 T>A; now c.359 T>A) mutation resulting in M44K (now M120K).10,11
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The aim of this study was to perform a detailed audiometric analysis of the
phenotype  of  USH3  patients  with  a  confirmed  genotype.  In  1995,  Pakarinen  (now
Kleemola) et al. presented part of the results from the nationwide study mentioned
above.12 It comprised the clinical manifestations, including audiometric,
ophthalmologic and vestibular examination results, of 42 USH3 patients.
Unfortunately, this report proved hard to obtain through medical library services in
non-Scandinavian countries and remained fairly unknown. Close co-operation
resulted in the present report, which comprises a more detailed analysis of the
audiometric findings bearing on an extended group of Finnish USH3 patients, whose
genotype had been established in the meantime (n=59).
Patients and Methods
Subjects
This study initially comprised 63 Finnish USH3 patients, who had been selected
because of their apparent progressive SNHI. Blood samples were collected from the
patients for linkage and mutation analysis. Linkage and mutation analysis of this
large sample of USH3 patients revealed the USH3A gene, which is described in
separate papers.10,11 Fifty-nine of them appeared to have homozygous Finmajor
mutations and 4 patients had compound heterozygous Finmajor/Finminor
mutations in the USH3A gene. After the exclusion of the patients of whom only one
audiogram could be obtained, 59 patients were available for longitudinal analysis of
SNHI.
Clinical examinations and audiometry
Medical history taking and ophthalmological examinations were performed on all
affected individuals.7,12 The latter included external eye examination, corrected
visual acuity measurements, Goldmann perimetry, slit-lamp microscopy,
ophthalmoscopy and electroretinography. The results of these examinations
confirmed a diagnosis of RP in all affected individuals.12 The patients were clinically
diagnosed  to  have  USH3  on  the  basis  of  medical  history  and  the  observed
progressive SNHI.
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Audiometric examination consisted of pure tone audiometry according to the norms
of the International Organization for Standardization.13 At ages 2-5 years, the first
examinations comprised behavioural (free-field) audiometry.
Speech recognition scores (percent correct recognition) were evaluated in 34
patients (3 with compound heterozygous mutations) using phonetically balanced
Finnish word lists.12 For each patient, the binaural mean maximum discrimination
score was derived from the two separate performance-intensity plots established for
monaural speech presentation.
Statistical analyses
Individual linear longitudinal regression analysis (binaural mean air conduction
threshold on age) was performed in all patients with sufficient (n=3 or greater)
longitudinal auditory threshold measurements covering a suitable follow-up
interval. A commercial program (Prism 4, GraphPad, San Diego, CA, USA) was used
for plotting and analysing the threshold data. The slope was called annual threshold
deterioration (ATD) and expressed in dB/year. Progression (ATD) was designated
significant when a significant positive slope (p < 0.025) was found. Systematic
significant progression of SNHI was concluded to exist if slopes of a significant
proportion of the measured audio frequencies were significantly positive (p < 0.05,
according to the appropriate binomial distribution).
Individual longitudinal regression lines were used for constructing individual Age-
Related Typical Audiograms (ARTA), i.e. threshold plotted in a compound audiogram
format for ages in decade steps.14 It should be emphasised that the ARTA were
limited to the frequency range of 0.25-8 kHz for compatibility with previously
reported ARTA. The purpose of applying ARTA was twofold: (1) it enabled a simplified
presentation of the often large number of serial individual audiograms in a compact
audiogram-like format with a clearer view on individual progression and (2) it
enabled simple age-corrected intersubject comparison between audiograms, as well
as simple comparison between individual ARTA and the overall ARTA (see below),
which was used as a reference, to outline intersubject variability in hearing
thresholds. For the second application, the individual mean across-frequencies (0.25-
8 kHz) threshold was calculated for a given audiogram obtained at a given age or for
all the audiograms pertaining to the fixed ages that constituted the ARTA. This
mean threshold was compared to the mean threshold obtained by performing
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exactly the same calculations using overall ARTA data, either at the appropriate
precise age (for the evaluation of a single individual audiogram) or at the fixed ages
(in decade steps) involved. Individual ARTA were only derived for methodological
reasons and not for the purpose of individual presentation.
Individual longitudinal binaural mean speech recognition scores, as well as single-
snapshot scores, were plotted against age and binaural mean PTA1,2,4 kHz (pure tone
average at 1, 2 and 4 kHz) level. A trend line was “fitted” where possible in either of
these plots in the way described in the Results section. The 90% correct score (X90)
was designated onset age for X=age and onset level for X=PTA1,2,4 kHz. The slope was
called deterioration rate in the performance-age plot and deterioration gradient in
the performance-impairment plot.
The equation of a saturation hyperbola with variable onset age was employed using
nonlinear cross-sectional regression analysis to fit the mean thresholds that were
derived for various ages to characterise the development of threshold with
advancing age (details below):
Y=Bmax (X - Xonset)/(Kd + (X – Xonset)),
where Y is threshold (dB HL), X is age (year), Bmax is the maximum (saturation)
threshold (dB HL), Kd (year) is a curvature parameter with the same units as age (the
smaller the Kd, the greater the curvature). Details about the hyperbola and the
fitting procedure have been previously described.15 In  the  present  modification  of
the nonlinear regression method, age (X) was substituted by age minus onset age
(Xonset), to the effect that also an estimate of onset age with its 95% confidence
interval was obtained.
Results
Pure tone thresholds
Serial audiograms (n=2 - 27) were obtained at ages between 2 and 54 years and
covered a follow-up interval of 1 - 40 years. Over 400 audiograms were analysed for
this study.
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Figure 1. Audiograms obtained from a selection of the 55 Finmajor/Finmajor patients, i.e.
patient  No.  1,  5,  9,  13,  17,  21,  25,  29,  33,  37,  41,  45,  49  and  53  (unshaded  panels)  and  the  4
Finmajor/Finminor patients, i.e. No. 56-59 (shaded panels). Binaural mean pure tone air
conduction thresholds are shown at 0.125-8 kHz. Patients ordered (from top left to bottom
right) by age (years) at last visit.
Figure 1 presents a selection of audiograms from patients with the Finmajor/
Finmajor  genotype in unshaded panels and the Finmajor/Finminor genotype in
shaded panels; the panels are ordered by the patient’s age (indicated in years) at the
last visit. In the patients with the Finmajor/Finmajor genotype, the audiogram
configuration varied from gently to steeply downsloping. These patients showed a
highly variable type and degree of progressive SNHI: from normal to moderate
hearing impairment at young ages to profound hearing impairment at more
advanced ages. The moment when only residual hearing was left could be reached
in the first up to the eighth decade of life. Moderate-to-severe SNHI was already
present at the first evaluation in one of the first decades of life or even in early
childhood. There were a few notable exceptions: patient 46 still had a close to
normal  threshold  at  the  age  of  23  and  patients  10,  21  and  43  only  showed  a  mild
threshold elevation at the ages of 12-14, 6 and 13, respectively (data not shown,
except for patient 21). The audiograms of the patients that belong to the same
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family were screened, controlling for age, to see whether their family relationship
(data not shown) was associated with any special features. Apart from the findings
related to the compound heterozygous patients, no such features were found.
The 4 patients with the Finmajor/Finminor genotype (Figure 1, shaded panels)
showed similar audiogram configurations as the Finmajor/Finmajor patients, but a
less  prominent  degree  of  SNHI  relative  to  age,  except  for  patient  58.  This  will  be
detailed in one of the next sections.
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Figure 2. Examples of serial audiometry indicating nonlinear progression in 3 different
Finmajor/Finmajor patients. Inset shows audiogram at first and last visit.
Progression of hearing impairment
Progression,  if  present,  seemed  to  be  most  prominent  within  the  first  part  of  the
follow-up interval. Figure 2 shows a selection of 3 patients whose follow-up
measurements were particularly suggestive of such a type of nonlinear progression.
It would seem that the highest degree of progression tended to occur at ages below
10 years. It seemed impossible to conclude whether SNHI had occurred already
congenitally or developed rapidly in early childhood. Regression analysis of the
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patients covered by Figure 2 including only threshold data obtained at age < 10 years
produced ATD values at the various frequencies in the range of 5-17 dB/year in
patient 15, 6-16 dB/year in patient 28 and 2-7 dB/year in patient 11.
In 40 out of 51 evaluable cases, a pilot longitudinal analysis over the whole follow-up
interval produced individual regression lines showing significant progression at 2-7
out of the 7 audio frequencies (significant). The degree of progression and the
thresholds involved varied substantially. Figure 3 illustrates this pilot analysis.
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Figure 3. Illustration of data underlying pilot analysis of thresholds at 1 kHz showing
(straight) individual longitudinal regression lines. Individual data points have been omitted
for  clarity.  Included  is  the  same  curve  as  shown  in  Figure  5,  which  was  derived  from  the
hyperbolic fit that was performed on the basis of the cross-sectional data included in Figure
4.
It includes all the straight regression lines that were fitted to the individual
longitudinal threshold data at 1 kHz (data points have been omitted for clarity). Also
included is the curve, a saturation hyperbola with variable onset age, which was
fitted to the cross-sectional mean thresholds derived in relation to Figures 4 and 5
(Patients and Methods). For each frequency, each individual regression line (shown
for 1kHz in Figure 3) could be characterised by an estimated median threshold during
follow-up and the ATD (data not shown). This could be related to either the
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corresponding median age during follow-up or the duration of follow-up (data not
shown). The ATD appeared to increase significantly with decreasing median age or
duration of follow up. The greatest variability in ATD was found at the younger ages
(or the shorter durations of follow up; see Figure 3), with tailing towards ATD values
as high as 20 dB/year (analysis and data not shown). Such parameter behaviour,
although the parameters pertained to (individual, longitudinal) linear regression
analyses (covering smaller parts of the overall age interval), is compatible with
overall nonlinear progression, as is clearly illustrated for 1 kHz in Figure 3.
Apparently, individual progression (as assessed by linear regression analysis over the
shorter individual age intervals) tended to be higher at relatively younger ages (or
relatively short follow-up intervals) than was reflected by cross-sectional
calculations (data not shown). Progression gradually slowed down at a more
advanced age (or at relatively long durations of follow up; see Figure 3).
Age-Related Typical Audiograms
Figure 4 includes all individual ARTA data plotted in superposition per fixed age (10,
20, 30, 40, 50 and 60 years) in decade steps  (second and third rows of panels) that
were used to derive overall ARTA (bottom panels). For each frequency, the across-
subjects mean threshold was calculated at each fixed age. The top row panels
include first-visit audiograms for two subgroups of patients aged below 10 years.
Invoking the data for these younger age groups, it was our intention to extend the
ARTA towards younger ages by including mean first-visit audiograms calculated
directly from the individual thresholds at the corresponding mean age at first visit.
However, we provisionally separated the first-visit audiograms for the patients aged
5 years and below from those for the group of patients aged 5-10 years because the
younger children mainly had behavioural audiometry (Patients and Methods). The
top left panel of Figure 4 clearly shows that the first-visit thresholds for the
youngest children (aged 2.1-4.9 years) were substantially higher than for the children
aged 5.5-9 years (top right panel). We therefore decided to exclude the threshold
data pertaining to the youngest age group from the calculation of ARTA
(Discussion). The bottom panels of Figure 4 show a combination of the mean
thresholds obtained for each age-related selection of audiograms or ARTA at fixed
ages, resulting in an overall ARTA. There is, however, an additional anomaly
involved: at all frequencies, the threshold seemed to decrease over the last two
decades. Figure 5 shows this more clearly.
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Figure 4. Top panels: first-visit individual audiograms obtained at the ages of 2.1-4.9 years
(mean 3.8 years, left) and 5.5-9 years (mean 7.2 years, right panel). Second and third rows of
panels: composite audiogram-like plots collected from individual ARTA covering the fixed
ages  10,  20,  30,  40  and  60  years.  Bottom  panels:  across-subjects  mean  threshold  for  the
separate fixed ages.
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This anomaly must have been caused by the fact that not each of the mean
thresholds calculated for the fixed ages (Figure 4) pertained to the whole group of
patients. The individual ARTA for each patient covered only a limited number of
fixed ages (in decade steps). The patient thus contributed only to the calculation of
the corresponding mean thresholds which, taken together, established the overall
ARTA for the whole group of USH3 patients. Thresholds calculated for different fixed
ages therefore could relate to different subgroups of patients, the oldest of whom
apparently had relatively better thresholds. Obviously, this anomaly could never
have occurred in individual longitudinal analyses. We therefore excluded the mean
thresholds at 60 years of age from the nonlinear regression analysis that was
performed to obtain curves approximating the threshold as it increased with
increasing age (Figure 5). The equation of a saturation hyperbola with variable onset
age was fitted to the remaining mean threshold data (Patients and Methods). The
estimates of onset age did not differ significantly across the frequencies according
to one-way analysis of variance (data not shown).
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Figure 5. Across-subjects mean thresholds taken from Figure 4 (bottom panels), now plotted
against the ages 7.2 and 10-60 years to evaluate progression. Vertical bars indicate 1 SE. The
curves were fitted with exclusion of age 60 years, using a nonlinear equation (see text).
Oblique arrow indicates an ATD of 9 dB/year.
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The mean across-frequencies onset age was 5.2 years (range 2.2-6.3), however, onset
age did not differ significantly from zero (i.e. age zero was included within the
estimated 95% confidence interval) at 4-8 kHz (data not shown). As shown in Figure
5, the fitted curves have their highest slope at age 7.2 years and below. The oblique
arrow is a reference ATD (slope) of 9 dB/year. This value was chosen for the occasion
because in Figure 6, the maximum vertical distance between the thresholds
estimated for (exactly) 7 and 10 years of age is 27 dB.
Figure 6 shows the overall ARTA (continuous lines) derived from the curves in Figure
5 (extrapolated to include the ages of exactly 7 and 60 years). The nonlinear
progression covered by the ARTA for USH3 in Figure 6 is reflected by threshold
increments that gradually decrease with increasing age. ARTA characterising USH1B
and USH2A are included in Figure 6 for the sake of comparison (Discussion).
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Figure 6. Overall ARTA (continuous lines) for Finmajor/Finmajor patients, derived from the
curves shown in Figure 5 (extrapolated to include ages 7 and 60). ARTA for USH2A (thin short
dashes) 16 and  USH1B  (bold  long  dashes) 17 are  shown  for  comparison.  Age  (in  years)  is
indicated in Italics. It can be noted that the thresholds of USH3 patients aged 7-20 years may
overlap with the thresholds of USH2A patients aged 10-60 years.
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Patients with Finmajor/Finminor mutations
Three of the 4 Finnish patients with this genotype (Figure 1, No. 56-59, shaded
panels) showed remarkably less SNHI than patients with homozygous Finmajor
mutations (No. 1-55). Their mean threshold (0.25-8 kHz) was derived along with their
mean  age  and  compared  to  the  mean  threshold  predicted  for  that  age  using  the
data on which the overall ARTA for the Finmajor/Finmajor patients were based.
These  mean  thresholds  were  better  by  38-40  dB  for  patients  57  and  59  (their
individual ARTA – data not shown - were fairly similar to those of USH2A patients)
and by 56 dB for patient 56 (ARTA even better than in USH2A patients), respectively.
However, the ARTA of the remaining Finmajor/Finminor patient (No. 58) were very
similar to the present overall USH3 ARTA derived for the homozygous Finmajor
genotype, with a mean threshold (88 dB) that was worse by 3 dB compared to the
mean threshold that was predicted for USH3 at the corresponding mean age (32.1
years) by the nonlinear regression equations underlying (Figure 5) the overall ARTA
data.
Speech recognition scores
Speech recognition scores are shown in Figure 7. Serial measurements were
available in 23 patients with homozygous Finmajor mutations; they comprised 2 - 7
measurements covering an interval of ages between 1 and 25 years. Single-snapshot
measurements were available from 8 patients. The phoneme scores are plotted
against the patient’s age (Figure 7A) and the level of SNHI (Figure 7B). Figure 7A
shows that speech recognition could begin to deteriorate appreciably (score <90%)
in individual cases from virtually any (onset) age above 5 years. Given the variability
in pure tone audiometry (Figure 3) this could have been expected. There was also a
great variability in deterioration rate: individual data indicate values ranging from
close to zero up to about 10% per year. The performance-impairment plot (Figure 7B)
showed less variability. A trend line was fitted with a presumed deterioration
gradient of 1% per dB hearing loss (HL). The intercept of the trend line was visually
fitted to obtain almost equal numbers of patients, no matter whether they had
single-snapshot or serial measurements that are represented by data points above
or below this line.  The onset level (PTA at score 90%) thus found was about 70 dB
HL.
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Figure 7a-b. Evaluation of speech recognition scores relative to age (A, performance-age
plot) and PTA1,2,4 kHz (B, performance-impairment plot) in 31 homozygous Finmajor/Finmajor
USH3 patients. Open circles and connecting hairlines: longitudinal measurements (23
patients); filled circle: single-snapshot measurement. Bold line: trend line fixed at slope –
1%/dB (see text); dotted lines: onset level (90% score) at 70 dB PTA1-4 kHz.
Longitudinal speech recognition scores were available in 3 of the 4 patients with
compound heterozygous Finmajor/Finminor mutations. The scores were fairly
similar to those of the homozygous Finmajor patients in relation to age and level of
SNHI  (data not shown).
Discussion
This study comprises a detailed audiometric analysis of the USH3 phenotype in fully
genotyped Finnish patients and thus allows for a more precise comparison to the
phenotypes  found  in  patients  with  other  types  of  Usher  syndrome.  As  previously
described, the Finnish USH3 patients showed an impressively wide spectrum of
SNHI.12 The present report focuses on the issues of nonlinear progression and
variation in degree and onset age of SNHI.
Recapitulation of audiometric findings
There is no doubt that the majority of the Finnish USH3 patients with homozygous
Finmajor mutations covered by this study had experienced substantial progression
in SNHI from early childhood onwards. It is unclear whether they also had any
substantial congenital SNHI, especially because there were a few exceptions
(Results). The results of the hyperbolic fitting procedure that was used to derive
overall ARTA suggest an onset age of about 5 years (Figure 5), but this finding should
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be regarded with great reservation as it derived from applying an arbitrary nonlinear
regression model.
From early childhood onwards, the patients showed a great variability in the level of
SNHI and the degree of progression. Part of the variability was clearly related to age
in a nonlinear way. The highest progression was found at the youngest ages and
gradually slowed down at more advanced ages (Figures 2 and 3). Analysis of speech
recognition scores in relation to age disclosed that in a small minority of the
patients the deterioration of speech recognition started so early and developed so
rapidly that the development of normal speech and language skills could have been
jeopardised.
Progression as a distinctive feature
Based on the results of this study we suggest that USH3 may be unique amongst the
Usher syndromes because of its high degree of (nonlinear) progression. USH3
patients showing more moderate progression than is indicated by the present
results may have been excluded from the present sample by the clinical selection
procedure that was followed. Even if that would be the case, the statement can be
upheld that the high degree of progression shown by many of our USH3 patients is
unique amongst the Usher syndromes. If the mean threshold at a given age and the
degree of progression in SNHI for the whole population of USH3 patients with the
Finmajor/Finmajor phenotype would be lower than our present estimates, it would
imply that the degree of variability in threshold and progression within that USH3
population is even greater than already could be pinpointed for the present, no
doubt selected, USH3 sample.
Selection bias
The thresholds in the group of children aged 2.1-4.9 years (Figure 4, top left panel)
were substantially higher than those in the group of children aged 5.5-9 years
(Figure  4,  top  right  panel).  Most  of  the  data  in  the  youngest  age  group  had  been
obtained using behavioural audiometry. When dealing with serial audiometry in
young children, in whom the first threshold measurements have been obtained with
behavioural methods, it is not uncommon to find that the first thresholds appear to
be higher than those obtained at a more advanced age with the usual clinical
methods. However, inspection of the longitudinal data of these children (not shown)
demonstrated  that  this  was  not  the  case  here.  The  children  appeared  to  have
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relatively high thresholds, including those obtained (later) with conventional clinical
audiometry. Although this does not exclude the possibility of an upward bias in the
behavioural threshold data obtained at the youngest ages, it does suggest the
possibility of an overall upward selection bias. Given the procedure of selecting the
patients with apparent progression in SNHI prior to mutation analysis, a selection
bias favouring high thresholds is bound to develop especially in the lower age
classes if that is where the highest degree of progression and variability tend to
occur. The latter features were indeed indicated by the results of a pilot analysis that
employed simple linear regression analysis (Figure 3) and for each individual related
the estimated median threshold and ATD to the median age during follow up or the
duration of follow up (Results). For that matter, it is possible that our whole patient
sample is biased towards high progression or relatively high thresholds resulting
from that progression.
Genotype-phenotype correlation in USH3
Some of the analysed patients with the compound heterozygous combination of
Finmajor/Finminor mutations showed relatively better hearing than the
homozygous Finmajor patients. This can be explained by the consequences of the
mutations. The Finmajor nonsense mutation (Y176X) causes a premature stop codon,
which leads to a truncated protein in homozygous patients. The Finminor mutation
(M120K) is a missense mutation by which methionine is replaced by lysine and thus
probably alters the protein less drastically. Speech recognition, however, seemed to
be fairly similar in relation to the level of SNHI. The function of the USH3A protein in
the cochlea and retina is still unknown. Adato et al.11 suggested that this protein
might be involved in cochlear hair cells and spiral ganglion cells. They speculated
that proper function could be maintained in early life by functional redundancy and
that time dependent loss of such potential redundancy occurs by unknown reasons.
We have no idea as to what could explain the high degree of intersubject variability
in the extent of hearing impairment in the group of homozygotes. It was even
present within the same sibships (data not shown). The 4 compound heterozygotes
showed a similar degree of variability as the homozygotes.
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Comparison of auditory features of Finnish USH3 patients to those
reported for Dutch USH1B and USH2A patients
Three previous studies comprised cross-sectional analysis of SNHI in USH2A
patients.16-18 The patients studied by van Aarem et al. and Wagenaar et al. were all
linked to the USH2A locus. Several of these patients were also included in the study
by Pennings et al.16, which only included patients in whom at least one mutation
was found in USH2A. SNHI in their USH2A patients was generally less severe and less
variable than was found in the present Finnish USH3 patients. The ARTA included in
Figure 6 illustrate that USH3 and USH2A patients may show fairly similar
progression at least at some ages or age intervals, as is indicated by the threshold
increments associated with decade steps in age. Pennings et al.16 found  a  pooled
ATD (across frequencies) of 0.5 dB/year. Figures 1-6 show that substantially higher
progression tended to occur in many of the Finnish USH3 patients during the first
decades of their life. This type of nonlinear progression displayed by USH3 may be
unique amongst Usher syndromes.
As previously suggested18, some of the Finnish USH3 patients with relatively good
hearing seemed to show a fair similarity in hearing thresholds to USH2A patients,
whereas some of the USH3 patients with relatively poor hearing seemed to have
audiograms (Figure 1) that looked fairly similar to those of USH1B patients.17,19
Indeed, the present analyses and comparisons demonstrate that a considerable
degree of overlap in audiometric phenotype is possible between USH3 and either
USH2A or USH1B.19. This is clearly suggested by the wide spectrum of variability in
the audiograms shown in Figure 1 and is illustrated by the ARTA in Figure 6.
Obviously, the pertinent difference between USH3 patients with an USH1B-like
audiogram and USH1B patients is that in the latter this type of audiogram is
congenital and stationary, whereas in the former it represents the final stage of
progressive deterioration. A related difference between these two patient groups
therefore is that a number of the USH3 patients have normal speech.
The importance of genotyping
The degree of overlap in the type of audiogram that is possible between USH1B,
USH2A and USH3 is a matter of special concern for the clinical diagnosis of Usher
syndrome. Given the high degree of variability in threshold features, phenotyping
might best be accomplished by collecting sufficient individual longitudinal data,
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covering an appropriate age range. A remarkable progressive hearing loss is from a
clinical viewpoint most likely compatible with USH3, but even when such data are
available it is still needed to base the genetic diagnosis entirely on the genotype
obtained through mutation analysis.
Audio-vestibular classification of Usher syndromes
Otterstedde et al.20 have suggested a new clinical classification of Usher syndromes
that distinguishes two subtypes: “vcUSH1”, a vestibulo-cochlear form and “cUSH1”, a
cochlear form of Usher syndrome type I. Their suggestion was based on the finding
of patients with USH1B-like audiograms and normal vestibular function. In the
Finnish study mentioned earlier, vestibular testing was performed on 17 USH3
patients. Vestibular function was normal in 9 patients (52%) and decreased in 8
patients (48%).12 In the light of these findings, the suggestion seems justified that
patients with “cUSH1” may turn out to be USH3 patients. In our opinion, knowing
the genotype of the patients involved, as far as molecular genetic analysis goes
anyway, is a necessary prerequisite when (re)considering clinical classifications
based on phenotype features. We suggest that the current audio-vestibular
classification of Usher syndromes can be maintained: however, it should clearly be
understood that USH3 patients may have intact vestibular responses and that their
distinctive audio-vestibular feature is the typical nonlinear progression in SNHI.
Comparison of speech recognition features between Finnish USH3 and
Dutch USH2A patients
The USH2A patients studied by Pennings et al.16 showed much more uniformity in
speech recognition scores related to age and the level of SNHI than the present
USH3 patients. The onset age of deterioration of speech recognition in these USH2A
patients could be pinpointed at about 40 years; the onset level was almost equal to
the present value of 70 dB in USH3 patients. The deterioration gradient in the USH2A
patients was 0.6%/dB, with a 95% confidence interval of 0.4-0.8%.16 Although we
were unable to obtain an estimate of the present deterioration gradient by
regression because of the presence of many replications (i.e. individual longitudinal
data) among the scores, we feel that the performance-impairment plots, including
the estimated onset level and deterioration gradient, were fairly similar in USH3 and
USH2A patients. For a detailed comparison of these data with previously published
data, we refer to Pennings et al.16
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Conclusions
The group of Finnish USH3 patients demonstrated an impressively wide spectrum of
progressive SNHI, with hearing thresholds that ranged from almost normal to
thresholds that are similar to those found in USH2A or even in USH1B patients. It is
uncertain as to whether part of the SNHI is already present at birth or develops from
early childhood onwards. Anyway, progression was most impressive during the first
and second decades of life and thereafter gradually declined in most patients
(Figures 2 and 3). Speech recognition started to deteriorate at highly variable ages.
Early deterioration of speech recognition may have jeopardised normal speech and
language development in some of the patients, whereas others still had remarkably
high recognition scores at a more advanced age despite considerably elevated pure
tone thresholds. Because of the high degree of variability in threshold features, it
seems preferable to base the diagnosis on the genotype obtained through mutation
analysis.
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Abstract
Purpose: To Evaluate of visual impairment in Finnish Usher syndrome type 3
(USH3) and compare this  with Usher syndrome types IB (USH1B) and 2A (USH2A).
Methods: We  carried  out  a  retrospective  study  of  28  Finnish  USH3  patients,  24
Dutch USH2A patients and 17 Dutch USH1B. Cross-sectional regression analyses of
the functional acuity score (FAS), functional field score (FFS*) and functional vision
score (FVS*) related to age were performed for all patients. The FFS* and FVS*
were calculated using the isopter V-4 test target instead of the usual III-4 target.
Statistical tests relating to regression lines and Student’s t-test were used to
compare between USH3 patients and the other genetic subtypes of Usher
syndrome.
Results: Cross-sectional analyses revealed significant deterioration in the FAS (1.3
% per year), FFS* (1.4 % per year) and FVS* (1.8 % per year) with advancing age in
the USH3 patient group. At a given age the USH3 patients showed significantly
poorer visual field function than the USH2A patients.
Conclusions:  The rate of deterioration in visual function in Finnish USH3 patients
was fairly similar to that in Dutch USH1B or USH2A patients. At a given age, visual
field impairment in USH3 patients was similar to that in USH1B patients but
poorer than in USH2A patients.
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Introduction
Usher syndrome, an eponym of the Scottish ophthalmologist Charles Usher (1865-
1942), is an autosomal recessive disorder that is characterised by the combination of
progressive retinitis pigmentosa (RP) and sensorineural hearing impairment (SNHI).1
Usher  syndrome is  estimated to  occur  in  3.5  to  6.2  in  100,000,  making it  the most
common cause of deaf-blindness worldwide2 Usher syndrome is divided into three
clinical types (I-III) on the basis of audiovestibular features and 13 corresponding
genotypes.3
Usher syndrome type I (USH1A-G) is characterised by congenital, profound SNHI, RP
and vestibular areflexia. Usher syndrome type II (USH2A-C) shows moderate to
severe congenital high frequency SNHI, RP and intact vestibular responses. Usher
syndrome type III (USH3) shows a highly variable type and degree of progressive
SNHI, RP and variable vestibular responses.4 The genetic subtypes USH1B and USH2A
account for about 75-80% of all Usher patients worldwide, whereas Usher syndrome
type III is rare.5 However,  Usher  syndrome  type  III  is  common  in  the  Scandinavian
countries and especially in Finland. Pakarinen et al.6  concluded that USH3 accounts
for 40% of all Finnish Usher syndrome patients.
A  Finnish  founder  mutation  is  associated  with  the  high  prevalence  of  USH3  in  the
Finnish Usher syndrome population.7 This mutation in the USH3A gene on
chromosome 3q21-q25 was designated Finmajor  (c.300 T>G;  c.528 T>G according to
the new nomenclature) and leads to a premature stop codon for a tyrosine at amino
acid position 176 (Y176X, previously Y100X).8-9  It has currently been identified in over
44 Finnish families as the cause of USH3 (unpublished results). The change in
nomenclature is the result of a newly identified exon that was discovered by Adato
et al. Another associated mutation is the Finminor (c.131 T>A; now c.359 T>A)
mutation resulting in M120K (previously M44K).8,9
Retinitis pigmentosa leads to impaired dark adaptation, progressive visual field
constriction and reduction in visual acuity (VA) in all types of Usher syndrome and
may  even  result  in  blindness.  Patients  with  USH3  have  been  reported  to  have
hypermetropia with astigmatism as opposed to hypermetropia without
astigmatism in USH1 and myopic refractive errors in USH2.10 Overall, 50% of patients
with Usher syndrome at some point develop posterior subcapsular cataract that
may severely hamper vision.11
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In 1996, Pakarinen et al. presented a report on the ophtalmological course of Usher
syndrome type III patients. However, it only included VA data for analysis and
comparison between the different clinical types of Usher syndrome.10 At that time,
the different genotypes in Usher syndrome had scarcely been identified. The VA and
visual field measurements of genetically confirmed Finnish USH3 patients were re-
analysed in the present study and compared to similar analyses of Dutch USH1B and
USH2A patients, identified by mutations in the MYO7A and USH2A genes,
respectively.12
Patients and methods
Subjects
This study included 28 patients (25 Finmajor-Finmajor and three Finmajor-Finminor)
with a clinically and genetically confirmed diagnosis of Usher syndrome type III.8
Routine ophthalmological examination included external eye examination,
corrected VA measurements, testing of refraction, Goldmann perimetry,
biomicroscopy and ophthalmoscopy. We included only those patients whose VA
scores and visual fields had been evaluated at least once. Data and patients were
collected retrospectively after a previous nationwide epidemiological study of Usher
syndrome type III in Finland conducted during 1989 – 1992. Medical records were
obtained, in accordance with local ethics committees and in co-operation with the
Finnish Ministry of Health, to include as many VA and visual field measurements as
possible. Data on vision field function were accepted without a priori criteria,
provided that functions had been reliably measured and data sufficiently
documented. The patients enrolled in this study were not selected according VA or
visual field findings.
Evaluation of visual acuity and visual field deterioration
Visual acuity was measured by using standard Snellen E-charts. Best corrected
measurements of both eyes were used for further evaluation. The VA measurement
for each eye was converted into a visual acuity score (VAS) according to Weber-
Fechner’s law. The functional acuity score (FAS) was determined by the equation FAS
= (3 x VASboth eyes + VASleft eye + VASright eye)/5.13
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Visual field size was evaluated by Goldmann perimetry in both eyes. The visual field
score (VFS), as defined by the American Medical Association in their 5th edition of the
Guides for the Evaluation of Permanent Impairment13, is related to the III-4 target.
Unfortunately, the available Finnish USH3 visual field data mainly involved the V-4
target and the III-4 target had hardly been measured. For this reason, visual field
scores  were  quantified  by  plotting  the  V-4  isopter  instead  of  the  III-4  isopter;  the
derived (V-4) scores are marked with an asterisk to designate the different isopter.
The corresponding visual field score (VFS*) for each eye separately and both eyes
combined were obtained by drawing 10 meridians in the visual field examination
form; two in each upper quadrant (at 25, 65, 115 and 155 degrees) and three in each
lower  quadrant  (at  195,  225,  255,  285,  315  and  345  degrees).  These  VFS*s  were
converted to a functional field score (FFS*) using a similar equation as for the
conversion of the VAS. Finally, the functional vision score (FVS*) was determined by
the FAS and the FFS* based on the equation FVS* = (FFS* x FAS)/100.13
To allow for a correct comparison of functional vision scores between the present
Finnish USH3 patient group and the previously published Dutch USH1B and USH2A
patient groups12, the field scores for the V-4 target (FFS* and FVS*) were derived in
the latter two patient groups as well. Special attention was paid to the quantitative
relationship between the parameters based on the III-4 target (FFS and FVS, precisely
as recommended by the American Medical Association) and the corresponding
newly defined parameters (FFS* and FVS*, respectively) based on the V-4 target. In
total, 17 USH1B and 24 USH2A patients had V-4 Goldmann perimetry examinations
and thus were included in the present analyses.
Statistical analysis
Regression analysis was used to analyse cross-sectional functional visual score data
(FAS, FFS* or FVS*) for the Finnish USH3 patients in relation to patient age.
Deterioration was concluded to be significant if the correlation coefficient was
negative at a probability level of < 0.025.
The regression data obtained for the functional visual scores (FAS, FFS* and FVS*) for
the Finnish USH3 patients were compared to the corresponding scores bearing on
the Dutch USH1B and USH2A patients.12 The regression lines were compared using a
procedure (Prism program, version 4, GraphPad, San Diego, California, USA) fairly
similar to covariance analysis. Regression lines were concluded to differ significantly
if either the F-test pertaining to the comparison between the slopes of these lines
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produced a significant value (p < 0.05), or - when the slopes were not significantly
different - if the F-test pertaining to the comparison between the elevations of the
lines (i.e. a measure for dispersion comprising grand means of both x and y values
for each subset of regression data) produced a significant value. Regression lines
were also compared using an optimum age window for the comparison in question.
Non-linear regression analysis was used to find the age at which the FVS* was 50%
and a 95% confidence interval (CI) was also obtained for this estimate.
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Figure 1. FAS, FFS* and FVS* for USH3, FinMajor homozygotes (solid triangles) plotted
together with the corresponding data for the Dutch USH1B (dots) and USH2A (open circles)
patients. Regression lines (dotted line, USH3; solid line, USH1B; dashed line, USH2A) are
included. Bold regression line indicates significant deterioration.  Small symbols represent
outlying values, which were excluded from regression analyses. Vertical hairlines show age
window (22-48 y). FinMajor/FinMinor compound heterozygotes are also plotted (solid
squares) but these data were excluded from regression and subsequent analyses.
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Results
Functional visual scores in USH3 patients compared to those of USH1B
and USH2A patients (cross-sectional analysis)
Figure 1 shows the FAS, FFS* and FVS* data for USH3 plotted together with those for
the Dutch USH1B and USH2A as previously published.12 All scores deteriorated
significantly for the USH3 patients. Although many of the FAS data for USH3
patients tended to be lower at more advanced ages than those measured for USH1B
or USH2A patients, there was no significant difference found between the
regression lines. Comparison of the FFS* or the FVS* data between the patient
groups showed a significant difference between the elevations of the regression
lines: at a given age, the highest scores belonged to the USH2A patients, whilst the
lowest scores belonged to the USH3 patients. The significant difference could be
attributed to the USH3 and USH2A groups. Corresponding differences were found
between the ages at which the FVS* equalled 50%. These ages were estimated at 28
for USH3 and 39 for USH2A; the estimated 95% CIs did not overlap (Table 1).
Table 1. Slopes (score “% change per year”) for the cross-sectional regression lines relating to
the FAS, FFS* and FVS* for USH3, USH1B and USH2A. Pooled slopes are included. The slopes
relating to the FFS or FVS (based on test target III-4 and previously published by Pennings et
al. 12) for USH1B and USH2A are shown in parentheses for comparison.
FAS FFS* (FFS) FVS* (FVS) Age at FVS* 50% (95% CI)
USH3 -1.3 -1.4 -1.8 28 (24-32)
USH1B -0.6 -1.6 (-1.3) -1.6 (-1.5) 33 (28-38)
USH2A -0.8 -0.9 (-1.0) -1.6 (-1.4) 39 (35-44)
pooled -0.9 -1.3 -1.7
There was no significant difference in slope detected between the three patient
groups. Applying the age window (Figure 1) did not introduce essential changes.
Table 1 lists the slopes for the cross-sectional regression lines relating to the FAS,
FFS*  and  FVS*  for  the  separate  groups  USH3,  USH1B  and  USH2A;  pooled  slopes  are
included. The slopes relating to the FFS for USH1B and USH2A, previously published
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by Pennings et al.12 are also included for comparison. The pooled slopes indicate that
the FAS deteriorated by a value of close to –1 % per year, the FFS* by a value slighty
below –1.5 % per year and the combined score FVS* by a value slightly over –1.5 % per
year. The parameter changes - from FFS to FFS* and from FVS to FVS* depending on
the target used - did not entail substantial changes in slope for the reference groups
USH1B and USH2A.
Data for the three heterozygous Finmajor-Finminor patients are shown in figure 1,
but were excluded from further analysis because of the small numbers of
observations. Nevertheless, it can be seen that these patients tended to show
relatively poor scores for their age.
FAS
10 20 30 40 50 60
0
20
40
60
80
100
(%) FFS*
10 20 30 40 50 60
0
20
40
60
80
100
(%)
FVS*
10 20 30 40 50 60
0
20
40
60
80
100
(%)
                                               Age (y)
Figure  2.  FAS,  FFS*  and  FVS*   for  USH3  (solid  triangles)  FinMajor  homozygotes.  Individual
longitudinal measurements connected by hairlines. Individual regression lines are included;
these are bold for significant deterioration. The bold dotted line is the regression line for the
cross-sectional USH3 data (Figure 1). Incidental longitudinal data of one FinMajor/FinMinor
compound heterozygote are also plotted (solid squares) without a regression line.
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Longitudinal data
Longitudinal data for USH3 are shown in Figure 2. Only one patient of the nine
patients for whom longitudinal regression lines could be calculated showed
significant deterioration of the FAS. Significant proportions of the patients
(according to binomial statistics) showed significant deterioration of the FFS* (six of
nine patients) or the FVS* (four of six). The slope of each individual longitudinal
regression line was compared to the slope of the corresponding overall cross-
sectional regression line (Figure 2, dotted line). Individual deterioration rates varied
fairly symmetrically around the slope for the corresponding cross-sectional
regression line and ranged from –2 to 0.6 for the FAS, -3.4 to 0.3 for the FFS* and
between –2 to –1.2 for the FVS*.
Discussion
The cross-sectional analysis in this study revealed a significant deterioration of the
FAS (1.3% per year), FFS* (1.4% per year) and FVS* (1.8% per year) with advancing age
for USH3 patients. This rate of deterioration in visual function was fairly similar to
that of USH1B or USH2A patients. The FVS* in USH3 patients was significantly poorer
than in USH2A patients; the 50% score was attained about one decade earlier in the
former. Inspection of the longitudinal data showed a rate of deterioration in visual
function similar to the results from the cross-sectional analysis.
The heterozygous Finmajor-Finminor patients tended to show relatively poor
functional vision scores compared to the homozygous Finmajor-Finmajor patients.
Because of the small number (n = 3) they were excluded from further analysis.
However, this is an interesting feature because the Finmajor-Finminor patients tend
to have better auditory function than homozygotes.4
Earlier studies on VA and visual field deterioration in Usher syndrome compared
USH1 patients and USH2 patients.12,14-20 In general, USH2 patients showed
(significantly) more favourable results than USH1 patients. Fishman et al.14
suggested that visual fields in USH1 deteriorate more rapidly than in USH2. Our data
confirms that at a given age the USH2A patients score better than USH1B patients;
however, a more rapid deterioration was not observed.
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The study on Dutch Usher syndrome patients found no significant difference in field
scores between patients with and without cataract.12.  For  this  reason  we  did  not
consider the issue of cataract in the analysis in our present study, although we
realise that cataract could cause a difference in functional vision scores.
The previously published report on visual function loss in USH3 patients describes
the course of visual handicap and typical refractive errors in USH3. Deterioration
occurred below the age of 40 years, VA dropped below 0.05 (severely impaired) at
the age of 37 and the visual fields were of tubular shape without any peripheral
islands at the average age of 30.10 They also suggested that hypermetropia with
astigmatism is pathognomonic for USH3.
As described under Patients and Methods, the standard visual field scores could not
be used in the analysis of the USH3 patient data. In order to check whether we could
use the V-4 target instead of the III-4 target, we used linear regression analysis (data
not shown), to compare between the FFS* and FFS scores, as well as between the
FVS* and the FVS data, for the Dutch Usher patients. It appeared that FFS* = FFS +14
and FVS* = FVS +14 over the whole range of scores involved. This finding implies that
the changes in evaluation parameters applied did not introduce any apparent
change in deterioration rate. The difference by a score of 14 should be kept in mind
when comparing the present altered scores (FFS* or FVS*) to scores according to the
original definitions (FFS or FVS). Thus, the FVS approximates the 50% score when
FVS*=64%.
Non-linear regression analysis focussing on FVS*=64% showed that, on average, for
USH3 patients the FVS attains values <50% at age >20 years, whereas this can be
expected to be the case at age >31 years for USH2A patients and ages >24 years for
USH1B patients. This is a clinnically important score because these patients (FVS <
50%) may no longer sufficiently benefit from vision enhancement techniques.13
It should be emphasized that most of the visual function deterioration in USH3
patients occurs after the deterioration in auditory function. Hearing deterioration is
most severe during the first decades of life.4
In conclusion,  the rate of deterioration of visual function in Finnish USH3 patients
was fairly similar to that in Dutch USH1B or USH2A patients. At a given age, visual
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field impairment in USH3 patients was fairly similar to that in USH1B patients but
significantly poorer than in USH2A patients.
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Abstract
Wolfram syndrome is a progressive neurodegenerative syndrome characterized
by the features Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and
Deafness (DIDMOAD). This multicentre study was conducted to analyse the
audiometric data of 23 genotyped Wolfram syndrome patients with
sensorineural hearing impairment. In all patients at least one mutation was
identified in WFS1. Pure tone threshold data were used for cross-sectional
analysis in subgroups of patients: male/female, young (<16 years)/old (19-25
years) and previously reported Dutch data/present additional multi-centre data.
With one exception, all subgroups showed a fairly similar type of hearing
impairment  with,  on  average,  thresholds  of  about  25  dB  at  0.25-1  kHz,  gently
sloping downwards to about 60 dB at 8 kHz. The subgroup of previously
reported Dutch female patients showed an exceptionally high degree of hearing
impairment. We could find no other reason than gender for this exception,
which was probably not related to the types of WFS1 mutations identified in
(most of) these females.
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Introduction
Wolfram syndrome is a progressive neurodegenerative syndrome characterized by
the features Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and Deafness
(DIDMOAD). It is an autosomal recessive inherited syndrome that was first described
by Wolfram and Wagner in 1938.1 Wolfram syndrome is rare with an estimated
prevalence of 1:770,000.2 Minimal clinical diagnostic criteria are juvenile-onset
diabetes mellitus and optic atrophy both mainly manifesting in the first decade of
life. In addition to the classical four features, patients can develop renal tract
abnormalities, apnoea, cerebellar ataxia, behavioral and psychiatric illness, gastro-
intestinal dysmotility and primary gonadal atrophy. In general, Wolfram syndrome
is a progressive neurodegenerative disorder that affects central, peripheral and
neuroendocrine components of the nervous system leading to death before or by
mid-life.3
Genetic studies have identified WFS1,  located  on  chromosome  4p16.3,  as  the  gene
involved in Wolfram syndrome.4,5 WFS1 codes for wolframin, a transmembrane
protein comprising 890 amino acids.5 Wolframin is expressed in the endoplasmatic
reticulum of a number of cell types in heart, lung, brain and pancreas.5,6
Immunostaining in developing murine inner ear  showed that wolframin localizes to
the canalicular reticulum, a specialized form of endoplasmatic reticulum, and is
involved in endoplasmatic reticulum stress responses, including apoptosis.7-9 The
canalicular reticulum has been identified in various types of inner ear cells, including
vestibular and cochlear hair cells, spiral ganglion cells, Deiter’s cells and cells in the
stria vascularis and is suggested to be involved in intercellular ion transport, an
important process in the physiology of the inner ear.3,7 However, the exact role and
function of wolframin remain unclear.
Mutations in WFS1 are not only responsible for the autosomal recessive Wolfram
syndrome, but also for an autosomal dominant form of non-syndromic
sensorineural hearing impairment designated DFNA6/14/38.10,11 Wolfram syndrome
is characterized by high-frequency sensorineural hearing impairment, whereas
DFNA6/14 is characterized by low-frequency sensorineural hearing impairment.12,13
Hearing impairment in DFNA6/14 can be either progressive or non-progressive.13
Mutation analysis of WFS1 in families with DFNA6/14 revealed that the identified
pathogenic mutations in this disorder all are small non-inactivating (missense)
mutations, whereas most of the pathogenic mutations in Wolfram syndrome
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patients are inactivating mutations.14 Of note is that Eiberg et al. described a family
with a missense mutation in WFS1 showing dominant optic atrophy associated with
hearing impairment and impaired glucose regulation.15
In 2004, Pennings et al. reported on 11 Dutch Wolfram syndrome patients with
confirmed mutations in WFS1. They concluded that progression in hearing
impairment mainly occurred in the mid- and high-frequency range. In addition, they
observed that the hearing impairment in 5 female patients with Wolfram syndrome
was substantially worse when compared to the hearing impairment in 4 male
patients.16 They hypothesised that this sex-related difference in hearing impairment
might be explained by the involvement of estrogen.16 Two remaining older patients
had a mild phenotype caused by two missense mutations in WFS1. Realizing that the
sex-related hearing impairment finding is only based on data collected in one centre
and on a small number of patients, we felt that it merits re-evalution in a multi-
centre study. Apart from that, collecting additional data allows us to further outline
the feature of sensorineural hearing impairment (SNHI) in Wolfram syndrome in
terms of presence and degree of progression and degree of variability. Therefore,
this multi-centre study was performed in close collaboration with co-authors of
previous clinical and genetic reports on Wolfram syndrome in order to obtain
audiometric data from genotyped Wolfram syndrome patients.
Patients and methods
This multi-centre study included 23 patients with Wolfram syndrome from whom
audiograms had been obtained and were judged to show clinically relevant SNHI. All
of them were previously diagnosed with Wolfram syndrome and in each of them at
least one mutation was identified in WFS1. After written informed consent,
audiological data were retrieved and, when necessary, patients underwent
additional audiometric evaluation in the respective local centres. Table 1 provides an
overview of the relevant data pertaining to the included subjects. In all patients,
only inactivating mutations in WFS1 were identified. For the sake of the Discussion,
we also performed an extensive study of literature, covering reports that appeared
before and after the review by Cremers et al. to trace audiograms of Wolfram
syndrome patients.12
Chapter 4.1
119
Table 1. Details of included Wolfram syndrome patients.
Origin Family
Patient
no. Gender Mutation(s) Ref.
Dutch WF1 1, 2 F, M Splice site (460+1G>A; 460+1G>A) 17
WF2 3 F Y528fsX542 17
WF3 4, 5 M, F Y508-L512del; Y508-L512del 17
WF4 6 F Y508-L512del; V412fsX440 17
WF6 7 M V509fsX517; V509fsX517 17
WF10 8, 9 M, F Q667X; V142fsX251 17
Austria 1 10 M L347fsX542; L347fsX542 18
United Kingdom - 11 M Q112X; Q112X -
France WS2 12, 13 M, F p.W540del; p.W540del 19
WS4 14 F p.W371X; p.W371X 19
WS7 15 M p.Y291X; p.S411fsX541 19
WS9 16 F p.V142fsX251; p.L554_G562del 19
Italy WS 17 – 23 3M, 4F Y454X; Y454X 20
Audiometry comprised measurement in a sound-treated room of pure tone
thresholds at octave frequencies 0.25 – 8 kHz for air conduction and bone
conduction according to common clinical standards. Bone conduction levels were
evaluated only to exclude conductive hearing loss.
Statistical analyses
Pure  tone  threshold  data  (binaural  mean  air  conduction  threshold)  were  used  for
cross-sectional analysis in subgroups of patients established by distinguishing 3
types of dichotomies: male/female, young/old and Dutch collective data16/present
additional multi-centre data. After a first inspection of the collective data, we
decided to classify patients aged 16 years or younger as “young” patients and those
aged 19-25 years as “old” patients. Three of the female patients of the study by
Pennings et al. had also been evaluated at higher ages (27-35 years); of the
additionally collected cases, only two had been measured at ages older than 25 years
(32 and 37 years). The cases only measured at age > 25 years were excluded from the
present study, however, one case (no. 7) showed a close-to-normal threshold at 0.25-
4 kHz at age 28.16 years and was therefore included in the age group of 19-25 years.
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B
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Figure  1  (A,  B). Individual binaural mean air conduction thresholds in 8 subgroups of
genotyped patients: (A), Dutch patients; (B), additional patients. (A) and (B) both include 4
panels. Panels on the left cover ages of < 16 years, panels on the right cover ages 19-25 years.
Top panels include male patients, bottom panels female patients. Of the Dutch patients
only the audiograms obtained within the intended age range are shown in the individual,
small panels. Age (years) is included in the symbol key to each small panel.
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Several of the Dutch patients had been measured at various ages. Their audiogram
data were included where possible in order to establish the “best possible” estimate
of the typical audiogram in relation to age. We realised, however, that different
samples bearing on the same individuals are not stochastically independent and
should therefore not be formally compared in cross-sectional analyses. Statistical
tests were only performed on stochastically independent samples (Results). One-
way analysis of variance was performed to compare across-individuals mean pure
tone thresholds at each frequency across a number (n>2) of subgroups. Student’s t
test was used to compare such mean values between relevant pairs of subgroups;
this test included Welch’s correction if Bartlett’s test detected unequal variances.
The level of significance used was p = 0.05 in each test.
Results
Figure 1 shows the individual audiometric data for air conduction obtained for all
genotyped patients with Wolfram syndrome, arranged in 8 subgroups. None of the
examined individuals showed an air-bone gap.
For each of the 8 panels shown in Figure 1 (A, B) a composite audiogram was drawn,
which only included the last-visit audiogram within the predetermined age range, to
check that pooling was allowed. This was indeed the case (data not shown) and the
“mean audiogram” resulting from averaging the included audiograms is shown in
each of the corresponding  panels of Figure 2 (A, B).
Statistical tests (Methods) demonstrated no significant differences in age between
any of the subgroups that were intended to cover the same age range. There was no
significant difference in mean threshold found at any frequency across any of the 4
subgroups pertaining to the additional cases (Figure 2B). We therefore conclude that
the additional patients do not disclose a substantial difference in hearing
impairment between the sexes or substantial progression in hearing impairment
with advancing age. No significant difference in mean threshold was observed at
any frequency within the subgroups of male patients pertaining to any of the
different subgroups (Dutch/additional patients, age <16 years/age 19-25 years). This
finding demonstrates that the males of the Dutch subgroup and the additional
present males showed a fairly similar degree of hearing impairment.
A significant difference in mean threshold was found at ages <16 years (left panels
of Figure 2A and Figure 2B) between the Dutch females (Fig. 2A, bottom panels) and
the additional females (Figure 2B, bottom panels) at the frequencies 1-8 kHz (p=
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0.005-0.03  in  Student’s  t-test).  At  ages  19-25  years  (right  panels  of  Figure  2A  and
Figure  2B),  there  was  only  a  significant  difference  in  mean  threshold  found  at  0.5
kHz (p=0.02) when testing between the subgroups relating to the Dutch and the
additional females, respectively. At the adjacent frequencies 0.25, 1 and 2 kHz,
however, Student’s t test produced p values of ~0.08 each; clearly, such a
constellation of findings cannot be attributed to chance alone (binomial statistics).
We conclude that the Dutch females showed a substantially higher degree of SNHI
than not only the Dutch males, as was concluded in the previous study, but also a
higher degree of SNHI than the additional collected females in the present study.16 It
should be noted that, although these females did show significant progression
according to the individual longitudinal analyses of our previous report,16 this
finding did not appear from the previous16 or the present cross-sectional analysis
(Figure 2A, bottom pannel). This apparent discrepancy may be due to the relative
large intersubject variability shown by the cross-sectional threshold data involved
(Figure 2A).
A B
Figure 2. Mean audiograms for the same subgroups as shown in Fig. 1: (A), Dutch patients;
(B), additional patients. Each separate, small panel includes a legend indicating sex (M,
male; F, female) and age range (0-16 years; 19-25 years). Bars above and below symbol are 1
SD each.
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Given the above described observations, it is clear that the subgroup of Dutch
females distinguished itself from the other subgroups of patients by its
substantially higher degree of SNHI. All additional patients (age <24 years) can be
simultaneously characterized in a satisfactory way by one “mean” audiogram with a
threshold of about 25 dB at 0.25-1 kHz, gently sloping down to about 60 dB at 8 kHz.
Implicit to this statement is the notion that none of these subgroups showed
substantial progression in SNHI with advancing age, at least throughout the first 3
decades of life.
We focused on using mutation data (Table 1) in pairwise comparisons by threshold
(Figure 1).  Controlling for mutation can be performed by comparisons between sibs
having the same mutations. The Italian sibs, patients 17-23, showed a remarkable
similarity of hearing thresholds regardless of gender and age (Figure 1B). The French
sibs (Figure 1B), patients 12 (male) and 13 (female), also showed similar thresholds,
however, the female sib was still young (12 years). Inter-sib comparisons within the
group of Dutch patients are especially intriguing because of the remarkbly poor
thresholds in the female patients.  The pair of sibs, patients 1 (female) and 2 (male),
reflect the previously described gender difference.16 Patient 1 showed a relatively
poor threshold even among the young Dutch female patients (Fig. 1A). Remarkably,
also her sib, patient 2, seemed to show a relatively poor threshold among the Dutch
males. The sibs patients 4 (male) and 5 (female) showed fairly similar thresholds at
age < 16 years. At a more advanced age, patient 5 (female) showed considerable
threshold deterioration, however, we had no threshold data for her sib, patient 4
(male), at a similar age. The pair of sibs patients 8 (male) and 9 (female), allowed for
comparisons within both age categories: there was no substantial difference
between them at age < 16 years, whereas a clear difference was shown at age 19-25
years (Fig. 1A), associated with the substantial deterioration shown by patient 9
(female), an effect that might be attributed to a gender effect.
Discussion
This study comprises a detailed audiometric analysis of genotyped Wolfram
syndrome patients. As described above, the hearing impairment in Wolfram
syndrome patients showed a fairly similar spectrum of SNHI in different subgroups
composed by dichotomising the total patient group by gender, age class and origin
(Dutch patients included in previous study vs additional patients in present study).
However, the subgroup of previously examined Dutch females stands out. Their
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hearing impairment is much more severe when compared to the other subgroups.
This finding seems difficult to explain. However, keeping in mind that any difference
in threshold may be due to differences in mutation and age, and perhaps also
gender, we focused on comparing thresholds while controlling for mutations
(Figure1). The factors mutation(s) and age could be simultaneously controlled for
only in a minority of cases. Pairwise threshold comparisons between the Dutch sibs,
patients 8 and 9, reflected the previously stipulated gender difference that became
prominent at a more advanced age. Multiple comparisons were possible within the
Italian sibship, patients 17-23 (Figure 1B), where no such difference could be
demonstrated. However, it should be emphasized that the maximum ages covered
by the Italian sibship were still < 22 years. Therefore, the possibility cannot be
excluded that the gender effect previously described for the Dutch patients, can be
substantiated in future studies, provided that sufficient data can be collected from
fully genotyped patients covering more advanced ages and allowing for adequate
controlling for mutations in the relevant analyses.
In an effort to extend on the current data, a literature search was performed in order
to obtain previously reported audiometric data. Figure 3 shows the audiogram data
of Wolfram syndrome patients with SNHI that could be retrieved.
Molecular genetic analysis was not reported for any of these cases. Their ages were
in the range of 10-14 years. There was no apparent difference between the male (top
panel in Figure 3) and the female (bottom panel) patients. For the sake of
comparison, we plotted the mean audiogram obtained for the present additional,
genotyped patients (see Figures 1B and 2B) aged <16 years (dotted line). All literature
cases except one (Pat 27 in Figure 3) had their threshold within 20 dB of this mean
threshold. It seems that our current audiometric data, with the exclusion of the
Dutch female subgroup, is representative for hearing impairment in Wolfram
syndrome patients.
Accepting the latter exclusion, we conclude that this unique collection of
audiometric data from the additional genotyped Wolfram syndrome patients shows
no significant sex-related differences, no substantial progression in SNHI with
advancing age and that their hearing impairment can be described by an audiogram
with a threshold of about 25 dB at 0.25-1 kHz, gently sloping downwards to about 60
dB at 8 kHz. It should be emphasized that the lack of gender-related differences in
threshold may be explaned by a general lack of cases of sufficiently advanced age.
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Figure 3. Individual audiograms for the Wolfram syndrome patients without genotype data
whose audiogram could be retrieved from literature (patients 2421,  25 and 2622, 2723,  28 and
2924, 30 and 3125, and 3226). Age 10-14 years. Top panel, male patients; bottom panel, female
patients. Same symbols and legends as in Figure 1; the dotted line indicates the mean
audiogram for the present additional, genotyped patients aged < 16 years.
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This thesis on hereditary hearing impairment elucidates some clinical and genetic
aspects of DFNA8/12 (Chapter 2), Usher syndrome type III (Chapter 3) and Wolfram
syndrome (Chapter 4).
Chapter 2 discusses DFNA8/12(TECTA)  and  provides  an  overview  of  the  hereditary
and audiological aspects of this type of hearing impairment. A general review of
DFNA8/12 is provided in Chapter 2.1 (in Dutch). In Chapter 2.2 we report on a novel
TECTA mutation, p.R1890C, found in a Dutch family with nonsyndromic autosomal
dominant sensorineural hearing impairment. In early life a, presumably congenital,
hearing impairment occurred in the midfrequency range, amounting to about 40 dB
at 1 kHz. The missense mutation is located in the zona pellucida (ZP) domain of ?-
tectorin. Mutations affecting the ZP domain of ?-tectorin are significantly associated
with midfrequency hearing impairment.
Since  2003,  one  of  the  foci  of  our  otogenetic  projects  has  been  on  families  with  a
midfrequency type of sensorineural hearing impairment. The DFNA8/12(TECTA)
family described above is the first large midfrequency hearing impaired family that
we studied, with linkage to the DFNA8/12 locus. Thus far, we could not find linkage
in three additional large midfrequency hearing impaired families. It will be
interesting to see whether in these other midfrequency families the mutations will
prove to be on the same locus, the locus of another type of DFNA, or perhaps a new
locus.
In Chapter 2.3 we present the results of an extensive audiological evaluation of five
selected members from the DFNA8/12(TECTA) family. The results were similar to the
specific audiological features previously obtained from a Dutch DFNA13(COL11A2)
family with midfrequency sensorineural hearing impairment.1 In this
DFNA13(COL11A2) family the mutations lead to an abnormal type XI collagen ?2-
chain, resulting in collagen fibril (type II collagen) disorganization in the tectorial
membrane.2 It appears that these types of midfrequency sensorineural hearing
impairment, caused by a defect in the tectorial membrane, may be characterized as
a cochlear type of conductive hearing impairment. This type of audiological testing
could lead to a new field of topo-audiological research, facilitated by otogenetic
family studies. Eventually, after further research, this type of testing might be useful
in determining the location of the defect.
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In children and young adults affected with midfrequency hearing impairment, it can
easily go unnoticed, because of the good speech reception scores associated with
the relatively favourable thresholds in the high frequencies. This situation is
comparable to speech perception in noise for normal hearing subjects, where the
emphasis  lies  on  the  perception  of  consonants  in  the  2-4  kHz  range.  Providing
adequate amplification can easily compensate the attenuation of sound in the inner
ear.  Hearing  aid  fitting  may  restore  hearing  close  to  normal.  However,  the
favourable thresholds for the low frequencies provide a challenge for optimal
hearing aid fitting, as the occlusion effect introduced by an earmold can put too
much emphasis on the low frequencies. Fitting with an open earmold may be the
best solution. In some cases the presence of progression can be troublesome. We
consider it worthwhile to continue our focus on midfrequency sensorineural hearing
impairment to support affected subjects needing specific audiological support and
guidance.
In Chapter 3 the phenotype of Usher syndrome type III (USH3) is discussed in great
detail. In the otogenetic literature a comprehensive report on this phenotype was
still lacking. Outside Finland USH3 is quite rare.3,4 The  high  prevalence  of  USH3  in
Finland is caused by the Finnish Disease Heritage, a collection of nearly 40 rare
hereditary diseases over-represented in Finland.5,6 In order to study this phenotype
we closely collaborated with Finnish colleagues, who were the first to identify this
type of Usher syndrome.
Chapter 3.1 describes the audiometric features in genotyped Finnish USH3 patients.
The group of Finnish USH3 patients demonstrated an impressively wide spectrum of
progressive sensorineural hearing impairment: from normal to moderate USH2A-
like hearing impairment at a young age to profound or even USH1B-like hearing
impairment at a more advanced age. The highest progression was seen during the
first two decades of life, gradually slowing down with further ageing. This type of
nonlinear progression may be unique amongst the Usher syndromes. Analysis of
speech recognition scores in relation to age also disclosed a highly variable
deterioration of speech recognition. The USH2A patients showed much more
uniformity in speech recognition scores related to age and the level of SNHI than the
present USH3 patients. However, the performance-impairment plots, including the
estimated onset level and deterioration gradient, were fairly similar in USH3 and
USH2A patients.
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Later, Sadeghi et al. published a phenotypical report on USH3 with quite similar
results and in addition they observed that vestibular function was variable, ranging
from normal to vestibular dysfunction.7 Because of the high degree of variability in
threshold features and vestibular function, it seems preferable to base the diagnosis
of USH3 on the genotype obtained through mutation analysis. Outside the
Scandinavian countries USH3 is rare and patients with USH3 may in fact be regarded
as USH1 or USH2 patients due to similarity with these clinical types or unfamiliarity
with the USH3 phenotype. The recent development and availability of the Usher
syndrome mutation microarray assists us to identify USH3 patients outside the
Scandinavian countries in a cost-effective way. Routine screening of mutations in all
currently known Usher syndrome genes are offered through this micro-array and
this is very helpful in the genetic counselling of not only USH3 patients but of all
patients with Usher syndrome.8
Chapter 3.2 evaluates visual impairment in Finnish genotyped Usher syndrome type
III patients and provides a comparison with visual impairment in patients with other
types  of  Usher  syndrome  (USH1B  and  USH2A).9 Most of the visual function
deterioration in USH3 patients occurred after the deterioration in auditory function.
The rate of deterioration in visual function in Finnish USH3 patients was fairly
similar  to  that  in  Dutch  USH1B  or  USH2A  patients.  However,  analysis  focussing  on
the clinically important functional vision score < 50% showed that this score, on
average, in USH3 patients is reached at age >20 years, whereas this can be expected
to  be  the  case  at  age  >31  in  USH2A  patients  and  age  >24  in  USH1B  patients.  Only
homozygous Finmajor-Finmajor USH3 patients were included in our analysis.
Surprisingly, the available data of compound heterozygous Finmajor-Finminor
patients  tended  to  show  relatively  poor  functional  vision  scores  compared  to  the
homozygote patients. This is an interesting feature because the Finmajor-Finminor
patients tend to have a better auditory function than homozygote patients.
Given the previous observations, it can be quite challenging to clinically classify the
various types of Usher syndrome. The only two features that stand out are the
degree of hearing impairment and vestibular function. However, in order to
differentiate between the three types it can be necessary to have sufficient follow-
up data available. The results of the present genotype-phenotype studies contribute
to the worldwide counselling of Usher syndrome patients and their relatives and can
be of great importance for future research. Gene therapy is one of the developments
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in Usher syndrome research that may lead to a possible curative therapeutic
intervention for this serious condition that affects both vision and hearing. Several
research groups are currently developing gene therapy for genetic subtypes of Usher
syndrome. A possible advantage for USH3 patients is the fact that the USH3 gene is
relatively small and can thus be placed much more easily in a gene therapy vector
like the adeno-associated virus than the other larger Usher syndrome genes.10
Future therapeutic studies of gene therapy in USH3 patients will focus on the effect
of the treatment. This will be done by studying the phenotype after intervention and
correlate this to the general deterioration known for a specific subset of patients. In
addition, this is one of the main reasons why studies of the phenotype are so
important for these patients.
Chapter 4 focuses on the phenotypical aspect of hearing impairment in genotyped
Wolfram syndrome patients. An international multi-centre study was conducted to
evaluate the degree and progression of sensorineural hearing impairment in
Wolfram syndrome patients. Furthermore, we examined whether or not the
previously reported gender-related difference existed.11 With  the  exception  of  the
group of previously reported Dutch female patients, all subgroups showed a fairly
similar type of hearing impairment with, on average, thresholds of about 25 dB at
0.25-1  kHz,  gently  sloping  downwards  to  about  60  dB  at  8  kHz.11 This degree of
hearing impairment was quite similar to the audiometric data of clinically
diagnosed Wolfram syndrome patients obtained from literature.12-17 It seemed that
our audiometric data, with the exclusion of the Dutch female subgroup, is
representative for hearing impairment in Wolfram syndrome patients.11 Accepting
the latter exclusion, our collected audiometric data from genotyped Wolfram
syndrome patients showed no substantial progression in sensorineural hearing
impairment with advancing age and no significant gender-related differences.
However, the possibility of gender-related differences in threshold at more
advanced ages could not be ruled out due to a general lack in cases of sufficiently
advanced age. The key to further clarifying the phenotypical aspect of hearing
impairment in Wolfram syndrome, as well as other features in these kinds of rare
syndromes lies, without doubt, in the continuing efforts to cooperate on an
international level. To examine further the hearing impairment in Wolfram
syndrome patients, it will be worthwhile to perform prospectively annual pure tone
audiometry in the currently known Wolfram syndrome patients. Analyses of these
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data may explain why there is a difference between the Dutch female patients with
Wolfram syndrome and the remaining patients.
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Summary
In  Chapter  2  the  phenotype  of  DFNA8/12  is  discussed.  A  review  of  this  disease  is
given  in  Chapter  2.1  (in  Dutch).  Chapter  2.2  reports  on  a  novel TECTA mutation,
p.R1890C, found in a Dutch family with nonsyndromic autosomal dominant
sensorineural hearing impairment. This presumably congenital hearing impairment
occurred  in  the  midfrequency  range,  amounting  to  about  40  dB  at  1  kHz.  Speech
recognition was good with all phoneme recognition scores higher than 90%. An
intact horizontal vestibulo-ocular reflex was found in four patients tested. The
missense mutation was located in the zona pellucida domain of ?-tectorin.
Statistical tests on genotype-phenotype correlations of the present and collective
data on DFNA8/12 revealed a significant association between the affected ?-tectorin
domain (zona pellucida or zona adherens) and the type of hearing impairment (mid-
or high-frequency), as well as a significant association between a cysteine-replacing
substitution and age-related progression in hearing impairment. Mutations
affecting the zona pellucida domain of ?-tectorin are significantly associated with
midfrequency hearing impairment. Substitutions affecting amino acid residues
other than cysteine show a significant association with hearing impairment without
progression.
Chapter 2.3 features the results of an audiological evaluation of five selected
members from this Dutch DFNA8/12(TECTA) family. In this study the audiometric
characteristics were evaluated with pure tone audiometry, loudness scaling, speech
perception in quiet and noise, difference limen for frequency, acoustic reflexes, oto-
acoustic emissions and gap detection. Four out of five subjects showed an elevation
of pure-tone thresholds, acoustic reflex thresholds, and loudness discomfort levels.
Loudness growth curves were parallel to those found in normal hearing.
Suprathreshold measures like difference limen for frequency modulated pure tones,
gap detection, and particularly speech perception in noise were within the normal
range. Distortion otoacoustic emissions were present at the higher stimulus level.
These results are similar to those previously obtained from a Dutch DFNA13 family
with midfrequency sensorineural hearing impairment. It seems that a defect in the
tectorial membrane results primarily in an attenuation of sound, whereas
suprathreshold measures, such as otoacoustic emissions and speech perception in
noise, are preserved fairly well. The main effect of the defects is a shift in the
operation point of the outer hair cells with near intact functioning at high levels. As
most test results reflect those found in middle-ear conductive loss, in both families
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the sensorineural hearing impairment may be characterized as a cochlear type of
conductive hearing impairment.
Chapter  3  describes  the  phenotype  of  Usher  syndrome  type  III.  In  Chapter  3.1  the
audiometric features, evaluated by serial pure tone audiometry and speech
recognition tests, in Finnish Usher syndrome type III patients with
Finmajor/Finmajor or Finmajor/Finminor USH3A mutations are presented. The
group of Finnish USH3 patients demonstrated an impressively wide spectrum of
progressive sensorineural hearing impairment: from normal to moderate USH2A-
like hearing impairment at a young age to profound or even USH1B-like hearing
impairment at a more advanced age. Compound heterozygous patients generally
showed a milder phenotype. The highest progression was seen during the first two
decades of life. Speech recognition started to deteriorate at highly variable ages. It is
uncertain as to whether part of the hearing impairment is already present at birth or
develops from early childhood onwards. Early deterioration of speech recognition
may have jeopardised normal speech and language development in some patients,
whereas others still had remarkably high recognition scores at a more advanced age
despite considerably elevated pure tone thresholds.
Chapter 3.2 evaluates visual impairment in these Finnish Usher syndrome type III
patients compared to other types of Usher syndrome (USH1B and USH2A). Cross-
sectional analyses revealed significant deterioration of the functional acuity score
(1.3 % per year), functional field score (1.4 % per year) and functional vision score (1.8
% per year) with advancing age in the USH3 patient group. The rate of deterioration
in visual function in Finnish USH3 patients was fairly similar to that in Dutch USH1B
or USH2A patients. Most of the visual function deterioration in USH3 patients
occurred after deterioration in auditory function.
Chapter 4 describes the results of an international multi-centre study on hearing
impairment in genotyped Wolfram syndrome patients. In all patients at least one
mutation was identified in WFS1. Pure tone threshold data were used for cross-
sectional analysis in subgroups of patients: male/female, young (<16 years) vs. old
(19-25 years) and previously reported Dutch data vs. present additional multi-centre
data. With one exception, all subgroups showed a fairly similar type of hearing
impairment with, on average, thresholds of about 25 dB at 0.25-1 kHz, gently sloping
downwards  to  about  60  dB  at  8  kHz.  The  subgroup  of  previously  reported  Dutch
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female patients showed an exceptionally high degree of hearing impairment. With
the exclusion of this subgroup, our audiometric data showed no substantial
progression in hearing impairment with advancing age and no significant gender-
related differences. Furthermore, it seemed that this data is representative for
hearing impairment in clinically classified Wolfram syndrome patients.
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Samenvatting
Dit proefschrift beschrijft klinische en genetische aspecten van DFNA8/12, het
syndroom van Usher type III en het syndroom van Wolfram. Hoofdstuk 2 is gewijd
aan het fenotype van DFNA8/12(TECTA) en wordt ingeleid met een review in
hoofdstuk 2.1 (in het Nederlands). In hoofdstuk 2.2 wordt een nieuwe mutatie
beschreven, p.R1890C, gevonden in een Nederlandse familie met een niet-
syndromaal autosomaal dominant overervend gehoorverlies. Dit vermoedelijke
congenitale komvormige gehoorverlies manifesteert zich in een dip van ongeveer
40 dB bij 1 kHz. Spraakverstaan was goed met foneemscores van meer dan 90%. De
horizontale vestibulo-oculaire reflex was bij alle vier geteste personen intact. De
missense mutatie is gelegen in het zona-pellucidadomein van ?-tectorine. Analyse
van genotype en fenotype toonde een significante associatie tussen het aangedane
domein van ?-tectorine (zona-pellucida of zonadhesine) en het type gehoorverlies
(midden- of hoogfrequent). Mutaties van het zona-pellucidadomein in het TECTA-
gen veroorzaken een gehoorverlies in de middenfrequenties, terwijl mutaties in het
zonadhesine domein met name een verlies in de hoge frequenties veroorzaken.
Verder blijken mutaties waardoor cysteïne is vervangen door een ander aminozuur
een progressief verloop van het gehoorverlies te veroorzaken.
Hoofdstuk 2.3 toont de resultaten van een uitgebreide audiologische evaluatie van
vijf leden van bovengenoemde DFNA8/12(TECTA) familie. In deze studie werden de
audiologische karakteristieken beoordeeld met behulp van toonaudiometrie,
luidheidsschaling, spraakverstaan in stilte en ruis, het juist waarneembare verschil
in frequentie, stapedius reflex drempels, oto-akoestische emissies en gat detectie.
Vier van de vijf personen lieten een verhoging zien van de gehoordrempel,
stapediusreflexdrempel en onaangename luidheidsdrempel. De luidheidsopbouw
verliep parallel aan de curve voor normaal horenden. Bovendrempelige metingen,
zoals het juist waarneembare verschil voor frequentie gemoduleerde tonen, gat-
detectie en vooral spraakverstaan in ruis lagen binnen het normale bereik. Distorsie
oto-akoestische emissies waren alleen aanwezig voor hoge stimuli. Deze resultaten
komen overeen met die van een eerder onderzochte Nederlandse DFNA13 familie
met middenfrequent gehoorverlies. Het lijkt erop dat een defect in het tectoriaal
membraan vooral resulteert in een verzwakking van het geluid. Bovendrempelige
metingen, zoals oto-akoestische emissies en spraakverstaan in ruis blijven relatief
goed behouden. Het voornaamste effect van de afwijking in het tectoriaal
membraan is het verschuiven van de drempel waarop de buitenste haarcellen
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werken. Omdat de testen grosso modo resultaten laten zien passend bij middenoor
pathologie, kan dit sensorineurale gehoorverlies worden opgevat als een conductief
cochleair gehoorverlies.
Hoofdstuk  3  belicht  het  fenotype  van  het  syndroom  van  Usher  type  III  (USH3).  In
hoofdstuk 3.1 worden de audiologische kenmerken, in de vorm van  toon- en spraak
audiometrie, voor Finse USH3 patiënten met Finmajor/Finmajor of Finmajor/
Finminor USH3A mutaties beschreven. De groep van Finse USH3 patiënten laat een
indrukwekkende variatie van progressief sensorineuraal gehoorverlies zien; van
normaal tot USH2A-achtig gehoorverlies op jonge leeftijd tot ernstig of zelfs USH1B-
achtig gehoorverlies. Over het algemeen hadden de heterozygoten een milder
fenotype. De progressie was het hoogst in de eerste twee decennia van het leven.
Het spraakverstaan ging op zeer uiteenlopende leeftijden achteruit. Het is niet
duidelijk of het gehoorverlies congenitaal is of dat dit zich later ontwikkelt. Bij
sommige patiënten is de spraak- en taalontwikkeling ernstig belemmerd door de
vroege achteruitgang van het spraakverstaan, terwijl bij anderen dit spraakverstaan,
ondanks aanzienlijk verlaagde gehoordrempels, op latere leeftijd opvallend goed
was.
Hoofdstuk 3.2 beschrijft het gezichtsvermogen van deze Finse patiënten en
vergelijkt dit met andere typen van het syndroom van Usher (USH1B en USH2A).
Cross-sectionele analyse toonde een significante afname van de functionele
gezichtsscherpte score (1.3 %/jaar), functionele gezichtsveld score (1.4 %/jaar) en
functionele visus score (1.8 %/jaar) met toegenomen leeftijd. De mate van de
achteruitgang is vergelijkbaar met dat van Nederlandse USH1B en USH2A patiënten.
De afname van de visus vond over het algemeen plaats nadat het gehoor was
verslechterd.
Hoofdstuk 4 zet de resultaten uiteen van een internationale multi-center studie
naar gehoorverlies in gegenotypeerde patiënten met het syndroom van Wolfram. Bij
alle patiënten was tenminste één mutatie geïdentificeerd in WFS1. De
gehoordrempels werden cross-sectioneel geanalyseerd voor verschillende
subgroepen: man/vrouw, jong (<16 jaar) vs. oud (19-25 jaar) en eerder beschreven
Nederlandse patiënten vs. aanvullende multi-center patiënten. Met uitzondering
van één subgroep was het gehoorverlies ongeveer gelijk, met gehoordrempels van
ongeveer  25  dB  bij  0.25-1  kHz,  die  zakken  tot  60  dB  bij  8  kHz.  De  subgroep  van
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Nederlandse vrouwen toonde een uitzonderlijke mate van gehoorverlies. Wanneer
deze groep buiten beschouwing wordt gelaten is er geen sprake van geslachts-
gerelateerde verschillen of substantiële progressie van het gehoorverlies. Het
gehoorverlies van de overgebleven patiëntengroep werd vergeleken met klinisch
gediagnosticeerde patiënten met het syndroom van Wolfram en bleek hiervoor
representatief.
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Dit proefschrift was nooit tot stand gekomen zonder de begeleiding, ondersteuning
en medewerking van de volgende personen.
Allereerst mijn promotor, prof. dr. C.W.R.J. Cremers. In ons eerste gesprek vertelde u
over de inhoud van een in de nabije toekomst door mij te vervaardigen proefschrift.
Naast de verrassing dat ik onderzoek ging doen naar voor mij onbekende syndromen
en afkortingen, die schijnbaar iets met gehoorverlies te maken hadden, herinner ik
mij vooral het enthousiasme waarmee u hierover sprak. Hartelijk dank voor uw
begeleiding, aanmoediging en correcties die zonder enige twijfel van grote waarde
zijn geweest voor het schrijven van dit proefschrift. Hiernaast was ik zonder u nooit
in exotische plaatsen als Panningen, Delfgauw en Vaassen geweest.
Dr. Ronald Pennings, mijn copromotor, collega en dankbaar aanspreekpunt binnen
de wondere wereld van de Otogenetica. Dit proefschrift bevat een drietal van je
kindjes die vanzelfsprekend niet zonder jouw inspanning het daglicht hadden
gezien.
Mijn andere copromotor, dr. Patrick Huygen. Fijn dat je deur altijd open stond en dat
je tijd vrijmaakte om samen aan onze hiervoor beschreven artikelen te sleutelen.
Also on behalf of those mentioned above, I would like to thank all international co-
authors, especially our Finnish colleagues Eeva-Marja Sankila end Leenamaija
Kleemola, who entrusted us their valuable data.
Dr. Dirk Kunst, stafarts en vervent otogeneticus, met wie ik regelmatig het
genoegen had om een familiedag in het UMCN of op locatie te organiseren. Ik heb
veel gehad aan je ideeën en adviezen. Ik verwacht dat je binnen dit veld nog vele
successen zult gaan boeken.
Dat laatste geldt ook voor jou, dr. Hannie Kremer, moleculair-geneticus en mijn
gids/tolk in de Antropogenetica. Bedankt voor je begeleiding. Ook gaat mijn dank uit
naar de medewerkers van je afdeling, met name dr. Arjan de Brouwer en dr. Rob
Colin, voor al het werk dat ten grondslag ligt aan dit proefschrift.
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Dr. ir. Arjan Bosman, audioloog van het volwassen audiologisch centrum en
geestelijk vader van de testbatterij beschreven in hoofdstuk 2.3. Hoog inzetten loont.
Hierbij wil ik tevens “je dames” hartelijk danken voor alle werkzaamheden die
hebben bijgedragen aan ons onderzoek.
Natuurlijk dank ik alle patiënten en hun familieleden, die welwillend hebben
meegewerkt aan dit onderzoek. Ook wil ik al het ondersteunend personeel van onze
afdeling bedanken voor de geboden hulp en in het bijzonder Diny Helsper-Peters
voor het verzorgen van de lay-out.
Al mijn collega arts-assistenten Keel-, Neus- en Oorheelkunde van het UMC St.
Radboud wil ik hierbij danken voor de in een enkel geval onderzoeksgerelateerde
inzet, maar bovenal voor de onze afdeling zo kenmerkende gezelligheid.
Mijn paranimfen, Lukas Lisowski en Bas Jongtien. Dit boekje kwam zonder jullie hulp
tot stand, maar ik hoop het samen, met de jongens, succesvol te gaan verdedigen.
Mijn familie en vrienden, van wie ik gelukkig kan zeggen dat ik niet het idee heb dat
de tijd die hier ingestoken is ten koste van jullie is gegaan. Het is fantastisch jullie
om me heen te hebben en om vooral over niet-medische zaken van gedachte te
kunnen wisselen. Ik hoop dat jullie allemaal op 1 juni naar Nijmegen kunnen komen!
Lieve Mama, Femke en Jurre, ontzettend bedankt voor jullie onvoorwaardelijke
steun (en de correcties van de Nederlandse stukken).
Tot  slot,  Eveline.  Ik  had  niet  durven  dromen  dat  jij  op  deze  plaats  zou  staan.  Het
afronden van dit laatste hoofdstuk van mijn proefschrift valt samen met het begin
van een fantastisch nieuw boek dat ik met jou wil schrijven.
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daar aan de RSG Magister Alvinus voor zijn eindexamen atheneum en ging
vervolgens Geneeskunde studeren aan de Universiteit Utrecht. Tijdens een coschap
Keel- Neus- en Oorheelkunde in Harvard’s Massachusetts Eye and Ear Infirmary te
Boston groeide zijn enthousiasme voor dit specialisme. Een keuzecoschap KNO van
acht weken in het Gelderse Vallei ziekenhuis (Ede) versterkte dat beeld. In februari
2003 solliciteerde hij met goed gevolg naar een opleidingsplaats tot KNO-arts in het
UMCN  St  Radboud.  De  basis  voor  dit  promotieonderzoek  is  gelegd  in  het  jaar
voorafgaand aan deze opleiding, die hij naar verwachting in september 2009 zal
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